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DISSERTATION ABSTRACT: 
 
HIV testing during pregnancy is the gateway to the HIV-related services that are part of the 
prevention of mother-to-child transmission (PMTCT) cascade. The virtual elimination of 
vertical HIV transmission cannot be achieved without universal antenatal care (ANC) HIV 
testing. Furthermore, women are at an increased risk of HIV infection and subsequent 
mother-to-child transmission (MTCT) during pregnancy. Emphasis has thus been placed on 
repeat testing during pregnancy among women who have a HIV-negative result at their first 
ANC test. Very little has been published on the current uptake and adherence to antenatal 
and repeat HIV testing in sub-Saharan Africa (SSA) countries.  
In line with the World Health Organization Guidelines, the Western Cape Prevention of 
Mother-to-Child Transmission of HIV (PMTCT) Clinical Guidelines in 2014 recommended a 
repeat HIV test between 32 - 34 weeks gestation and again at delivery in addition to testing 
at “booking” (< 20 weeks gestation), meaning that there were three “testing windows” 
during which pregnant women not previously diagnosed as HIV-infected should undergo 
testing. Between 2013 and 2016 the Closing the Gaps study established an electronic PMTCT 
register (e-register) that consolidated routine care data from a primary healthcare facility 
and its secondary and tertiary referral sites in Cape Town, South Africa. This provided a 
single longitudinal record, from antenatal care to delivery, for each pregnant woman which 
enabled the longitudinal assessment of maternal HIV testing uptake and treatment. Utilizing 
these data, we conducted a retrospective sub-analysis investigating the implementation of 
PMTCT HIV testing guidelines (until delivery), in Cape Town, for the period 1 July 2014 – 31 
December 2016. The main objectives of the study were to assess the coverage and timing of 
initial HIV testing during pregnancy, the completion of HIV testing at “booking” and within 
the recommended testing windows (including delivery), HIV prevalence and incidence at the 
recommended testing windows, and the predictors of missed testing opportunities. 
The research protocol (Part A) was designed to describe the proposed significance, 
objectives and methodology of the study. 
The literature review (Part B) critically evaluated available literature on: antenatal and 
repeat HIV testing proportions, HIV positivity, the feasibility and acceptability of repeat 
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testing, and the predictors of testing completeness within different SSA countries, for the 
period 2010 – June 2018. Its aim was to inform this study. The need for post-Option B+ 
implementation, longitudinal studies that analyze antenatal and repeat HIV testing coverage 
and implementation within SSA was identified. 
In Part C I present the methods, results and interpretation thereof for the analysis of 
individual-level, longitudinal, maternal HIV-testing patient data from the Closing the Gaps 
study e-register as a manuscript to be submitted for publication. 
Among 8558 women who delivered at either the primary care facility or its referral sites, 
7213 were not diagnosed HIV-positive prior to their first visit and thus eligible for testing in 
pregnancy. Among these women, 91% received ≥1 HIV test and 85% “booked” >5 days 
before delivery with 98% testing completeness at “booking”. Only 49% of women eligible for 
testing “booked” ≤22 weeks gestation. Among women that “booked” ≤22 weeks gestation 
who weren’t diagnosed HIV-positive before delivery and delivered >5 days after the start of 
the third trimester, 10% received tests in all three recommended windows. Thirty-one 
percent of women that had not been diagnosed HIV-positive before delivery had an 
uncertain (i.e. last tested ≥3 months before delivery) or unknown (i.e. never tested) HIV 
status after delivery. Out of the women that had a known HIV status at delivery, 21% were 
HIV-positive of whom 95% were known HIV-positive before current pregnancy and 4% were 
diagnosed at “booking”. Overall, HIV incidence in those with ≥2 HIV tests during 
pregnancy/at delivery was estimated to be 0.2% between “booking” and delivery. Women 
who enrolled after 2014 were less likely to miss ≥1 of the three recommended tests (aOR: 
0.70; CI: 0.55 – 0.90) and not test at delivery (aOR: 0.63; CI: 0.55 – 0.71) compared to those 
who enrolled in 2014.  
Conclusion: In our study, HIV testing completion at “booking” was high, but women tended 
to “book” late during pregnancy resulting in late initial testing and missed opportunities for 
early HIV diagnosis. Implementation of repeat HIV testing is poor, particularly at delivery. 
HIV incidence between first negative ANC test and delivery is very low and therefore future 
studies to assess the most cost–effective number and timing of HIV tests, and feasibility of 
implementation, should be considered. Overall, maternal HIV testing within the PMTCT 
programme in Cape Town has matured post 2014 with improved implementation over time.   
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PART A: RESEARCH PROTOCOL 
SYNOPSIS 
 
Title: A longitudinal analysis of the completeness of maternal HIV testing, including repeat 
testing, during pregnancy, and the predictors thereof, in Mitchell’s Plain, Cape Town. 
Background and justification: Despite significant reductions in the mother-to-child 
transmission (MTCT) of HIV in South Africa (SA) the virtual elimination of vertical 
transmission (and the validation thereof) remains elusive. This is due to coverage gaps in the 
prevention of mother-to-child transmission (PMTCT) care continuum of which maternal HIV 
testing is the entry point. There is evidence that virtual MTCT elimination cannot be reached 
unless near universal antenatal testing is achieved. Complete maternal HIV testing including 
repeat testing in late pregnancy/delivery is important as pregnant women are at increased 
risk for HIV infection and mothers with acute rather than chronic HIV infection are more 
likely to vertically transmit HIV. Since July 2014 the Western Cape (WC) PMTCT guidelines 
recommend a minimum of three maternal HIV tests for pregnant women of 
negative/unknown HIV status: 1) at the first antenatal care (ANC) visit (< 20 weeks); 2) at the 
third trimester ANC visit; 3) in labour or within a few days post-partum. PMTCT coverage is 
currently determined using aggregate reporting at each step of the continuum. As a result, 
there is little individual-level information on the implementation and coverage of maternal 
HIV testing, including repeat testing, in SA. Aggregate level reporting is likely to 
overestimate the true maternal HIV testing coverage when taking each individuals uptake of 
the repeat testing continuum into account.  
Objective: Utilizing longitudinal maternal data from the Closing the Gaps (CTG) study, this 
sub-analysis will examine: the coverage of HIV testing at recommended time points within 
the PMTCT continuum; HIV prevalence and incidence; and the factors associated with 
testing incompletion during pregnancy. By doing so we hope to provide direction to the 
targeting of future interventions for the effective closure of identified gaps. 
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Methods: This is a descriptive longitudinal retrospective cohort sub-analysis conducted on 
consolidated maternal HIV test data obtained from the novel integrated PMTCT electronic 
register (e-register) implemented during the CTG study. Data was obtained from existing, 
routinely collected, maternal data sources of Mitchell’s Plain Midwife Obstetric Unit 
(MPMOU) (primary level) and its secondary and tertiary level referral sites: Mitchell’s Plain 
District Hospital (MPDH), Mowbray Maternity Hospital (MMH) and Groote Schuur Hospital 
(GSH) respectively, within the Klipfontein sub-district of the WC. We will include women 
that attended antenatal care and/or delivered at either MPMOU or one of its referral sites 
with a live or still birth pregnancy outcome between July 2014 and December 2016. Both 
women for whom no pregnancy outcome can be found and those who “booked” (i.e. 
presented for ANC >5 days before delivery) at basic antenatal clinics will be excluded from 
the study as full testing data cannot be determined. No patient contact or involvement is 
required for this study and data will be de-identified prior to analysis. 
Testing completion, HIV prevalence and incidence will be described using descriptive 
statistics. Logistic regression will be used to determine potential predictors of not testing: at 
all, at “booking”, at delivery, and missing one of the three recommended tests. 
Ethical considerations: The CTG study received ethical approval from both the University of 
Cape Town Human Research Ethics Committee (UCT-HREC) (HREC: 145/2013) and the 
Provincial Government of the Western Cape Department of Health Research (RP063/2013). 
Risks and Benefits: The main risk to study participants in this sub-analysis is that of 
breaching patient confidentiality. Significant precautionary measures will however be in 
place throughout the study process to protect patient confidentiality, thus rendering the 
study minimal risk. The inclusion of folder numbers as a data linkage field is necessary for 
the consolidation and cleaning of episode and test data but will be removed from the 
dataset prior to analysis.  
The proposed study will not directly benefit participants. It will however, provide important 
insights into the individual level PMTCT HIV testing coverage gaps which could, through 
targeted interventions, potentially benefit individuals at a local and international level in the 
future. 
3 
 
Informed Consent: Data collection for the CTG study did not require participant recruitment 
as it was routinely collected by health services. A waiver of informed consent was therefore 
granted for the construction of the e-register. No additional participant recruitment is 
required for this sub-analysis. 
Privacy and confidentiality: Once the linkage of episode and maternal HIV test data is 
complete participant identifiers will be removed to anonymize the dataset. All data will be 
password protected and securely stored on the UCT firewall-protected SQL server housed 
within the CIDER offices. Only authorized NIH Human Subjects Protection trained 
researchers will have data access. Essential data transfer will be safeguarded by password 
protected encryption and compression.  
Involvement of vulnerable persons: The data to be analyzed in this study is that of pregnant 
women, a vulnerable population. These women are the group of interest to whom all study 
findings will be inferred and therefore the inclusion of their data in this study is necessary. 
Research related compensation and insurance: The proposed project is a secondary data 
analysis and there will therefore be no compensation or potential injury to study 
participants. 
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PROTOCOL 
 
A longitudinal analysis of the completeness of maternal HIV testing, including repeat 
testing, during pregnancy, and the predictors thereof, in Mitchell’s Plain, Cape Town. 
1. Purpose of the study 
 
 Study Aims and Hypotheses 
 
Aim:  
To investigate the HIV testing coverage gaps in the prevention of mother-to-child 
transmission (PMTCT) care continuum, estimate HIV prevalence and incidence, and 
determine the predictors associated with testing incompletion amongst pregnant women in 
Mitchell’s Plain, Cape Town.  
Hypotheses:  
I. Testing completion will be lower at subsequent versus initial antenatal care visits 
(booking), among women not diagnosed as HIV-positive. 
 
II. Testing completion among pregnant women with an unknown/negative HIV status 
who present for the first time at delivery will be low. 
 
III. The testing completion proportion for each time point as determined by data 
recorded using a novel electronic register of PMTCT coverage (PMTCT e–register) will 
be lower than that reported in the literature using aggregate provincial and/or 
national data. 
 
IV. There are patient-level, facility-level, and calendar time-level characteristics that are 
predictive of testing incompletion.  
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 Study objectives 
 
• To describe the proportion of HIV unknown/previously negative women receiving at 
least one HIV test during pregnancy or delivery.  
 
•  To describe the timing of first-time maternal HIV testing among pregnant women of 
unknown/previously negative HIV status. 
 
• To describe maternal HIV testing completion at “booking” (first antenatal care visit) 
among HIV unknown/previously negative women who receive antenatal care and at 
delivery among HIV unknown/previously negative who don’t receive antenatal care. 
 
• To describe the PMTCT programme repeat HIV testing completion, among pregnant 
women who initially presented as HIV-negative, at each recommended testing step 
of the continuum of care (until delivery) and with respect to each individual’s 
progress through the care continuum. 
 
• To describe the HIV prevalence and incidence among the above-mentioned women 
at each recommended testing step of the care continuum up until delivery. 
 
• To determine the predictors of missed testing opportunities, among the above-
mentioned women, overall and at each testing step of the care continuum (up until 
delivery). 
2. Background and justification 
 
In 2011 South Africa (SA) was listed as 1 of the 22 countries that accounted for 90% of  
pregnant HIV-positive women globally and was prioritized as part of the Global Plan to 
eliminate new cases of HIV infection among children by 2015 [1]. SA has since made great 
progress in achieving the goals of the Global Plan, accomplishing an 84% reduction in the 
number of new mother-to-child transmission (MTCT) infections and meeting the target of  
6 
 
 
reducing its MTCT rate to 2% [1,2]. Despite the progress made in SA, coverage gaps within 
the PMTCT care continuum still occur and as a result virtual elimination of MTCT and 
moreover validation thereof have been elusive [3–6]. Closure of these gaps is essential to 
ensure the survival of each mother-infant pair.  
A recent study conducted by Woldesenbet et al. illustrated that in SA 35% of mothers 
dropped out of the PMTCT continuum at one step or another and furthermore that a third 
of MTCT was attributable to missed opportunities within the PMTCT care continuum [5]. In 
order for a PMTCT program to be effective a woman and her infant require not only access 
to, but also engagement in a continuum of interventions (Figure 1) [7: p.19-27], namely: 
Antenatal services and HIV testing throughout pregnancy and at birth; the initiation of 
antiretroviral therapy (ART) if HIV-positive and uptake of the corresponding PMTCT 
Figure 1. Brief outline of the steps in the prevention of mother-to child-transmission (PMTCT) 
continuum [7: p.19-27]  
ANC= Antenatal care 
ART = Antiretroviral therapy 
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counselling; safe childbirth practices as well as appropriate infant feeding; and postnatal 
services including mother and infant HIV testing and the initiation of ART if necessary [2,7]. 
As the point of entry to the HIV services offered to women in the PMTCT care continuum, 
antenatal HIV testing is a critical step in the pathway to the elimination of MTCT [8]. Early 
testing and diagnosis of undiagnosed HIV-positive pregnant women provides them with 
immediate access to lifelong triple ART which, if adhered to, will offer protection against 
MTCT during current and subsequent pregnancies [9]. 
There is evidence that maternal HIV 
testing, alongside maternal and 
infant ART initiation, is accountable 
for the majority of the gaps in the 
PMTCT continuum. Moreover, 
virtual MTCT elimination cannot be 
reached unless near universal 
testing is achieved [5,10,11]. A 2012 
study by Stinson et al using cord 
blood surveillance illustrated that 
even in a well-resourced setting 
incomplete antenatal testing 
contributed 46% toward missed 
PMTCT opportunities (Figure 2, bar 3) [10: p.202]. Of those mothers identified as HIV-
positive via cord blood, 16% had not been tested for HIV during pregnancy (Figure 2, bar 2) 
[10: p.202].  
Since the implementation of immediate lifelong triple ART for all HIV-positive pregnant 
women (Option B+) in 2015 the majority of South African, previously undiagnosed, HIV-
positive pregnant women are initiated on ART at their first antenatal care (ANC) visit, if 
identified [12]. This is likely to result in a greater proportion of MTCT arising from pregnant 
women who test HIV-negative at their first ANC visit and then seroconvert during pregnancy 
or postpartum [13]. This is substantiated by evidence that pregnant women are at increased 
risk for HIV infection and that, in addition, the risk of MTCT is elevated among women with 
acute rather than chronic HIV infection [14–19]. This highlights the importance of complete 
Figure 2. Missed opportunities within the PMTCT continuum 
in the Western Cape. Adapted from Stinson et al [10: p.202]. 
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repeat HIV testing during pregnancy in identifying women who seroconvert subsequent to 
their first ANC test, enabling them to initiate ART as soon as possible thereafter, thereby 
limiting MTCT. This will furthermore ensure that HIV exposed infants are identified, followed 
closely, and tested and initiated on ART early if infected [16,20]. HIV testing early-on in 
pregnancy is necessary to deem women eligible for HIV retesting in the third trimester of 
pregnancy or at delivery. This is particularly important for those at risk of seroconversion 
[21]. 
Recognizing the importance of repeat testing during pregnancy, the July 2014 Western Cape 
Prevention of Mother-to-Child Transmission of HIV (PMTCT) Clinical Guidelines Update 
recommended an HIV test at delivery/immediately post-partum for women of 
negative/unknown HIV status, in addition to the already suggested tests at the first (<20 
weeks gestation) and 32-34 weeks gestation ANC visits [22]. This recommendation was also 
included in the national consolidated guidelines in April 2015 [7]. There is however little 
information on the implementation and uptake of HIV repeat testing among pregnant 
women at the individual level. This largely results from aggregate coverage reporting of 
each step of the PMTCT care continuum separately, rather than tracking individual women 
longitudinally through pregnancy and post-partum. 
Up until now the data that are used to determine service coverage in SA are routinely 
collected, collated and summarized in paper format at the facility level and then sent 
monthly to the sub-district level for electronic capture before being imported into the 
District Health Information System (DHIS) [23]. There are however concerns about the 
quality of recorded PMTCT data, mainly due to the inaccuracy and incompleteness of its 
reporting [23,24]. Moreover, the PMTCT care continuum is implemented sequentially 
throughout pregnancy and involves multiple service providers, ultimately resulting in the 
collection of data across facilities and at different steps throughout the continuum [10,23]. 
This approach accounts for aggregate reporting of PMTCT coverage with no linkage across 
the different platforms and consequently no tracking of an individual pregnant woman’s 
progress through the care continuum [25]. It may therefore appear as though there is 
sufficient HIV testing coverage at an aggregate level whereas this is likely to be an 
overestimate of the true coverage when taking each individuals uptake of the repeat testing 
continuum into account. 
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In 2014 the Closing the Gaps (CTG) study (Appendix 2) implemented the integration of a 
PMTCT electronic register (e-register) within the existing service platform at Mitchell’s Plain 
Midwife Obstetric Unit (MPMOU) as well as its referral sites as part of an active PMTCT 
surveillance system. Its aim was to merge data recorded at different steps of the PMTCT 
continuum so as to be able to holistically compare the coverage and effectiveness of the 
PMTCT programme before and after implementing the system. The e-register provided a 
longitudinal PMTCT record for each women delivering at MPMOU or its referral sites, 
allowing individual-level assessment of HIV testing from the first ANC visit through to 
delivery. 
Antenatal HIV testing early on in one’s pregnancy is essential to the elimination of MTCT [8]. 
Furthermore, with perinatal seroconversion prominently contributing to vertical MTCT great 
emphasis has been placed on the importance of repeat HIV testing throughout the 
pregnancy period [6,13,16,22]. There has however been limited assessment of the antenatal 
HIV testing coverage specifics and implementation of repeat testing in SA. Utilizing the 
availability of longitudinal maternal data from the CTG study this sub analysis will 
investigate: the coverage of maternal HIV testing, including repeat testing, within the 
PMTCT continuum; HIV prevalence and incidence; and the factors associated with testing 
incompletion during pregnancy amongst women that attended antenatal care and/or 
delivered at either MPMOU or one of its referral sites in the Western Cape (WC). By doing 
so we hope to provide insight into where future interventions should be targeted in order to 
effectively close identified gaps. 
3. Methodology 
 
 Study design 
 
A descriptive longitudinal retrospective cohort study will be conducted, for the period 1 July 
2014 – 31 December 2016, on secondary maternal HIV test data obtained from the novel 
integrated PMTCT e-register implemented during the primary CTG study (Appendix 2).  
There will be no direct contact with research participants in this study. 
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The PMTCT e-register was established as one of three linked monitoring and surveillance 
interventions in the primary NIH-funded CTG study. The e-register, specific for MPMOU and 
its referral sites, consists of consolidated routinely collected data elements from antenatal 
HIV testing registers, labour ward HIV PMTCT registers and delivery registers as well as HIV-
associated laboratory and ART data. 
 
 Study setting 
 
Data to be analyzed in this study was obtained in the CTG study from the existing data 
sources of MPMOU and its secondary and tertiary referral sites: Mitchell’s Plain District 
Hospital (MPDH), Mowbray Maternity Hospital (MMH) and Groote Schuur Hospital (GSH) 
respectively, within the Klipfontein sub-district of the WC, SA. MPMOU is a primary health 
care facility providing both antenatal care services, including HIV testing, counselling and 
treatment, and uncomplicated vaginal delivery services which are administered by 
midwives. MMH and MPDH are secondary level facilities with operating theatres and 
neonatal intensive care unit (ICU) facilities respectively. GSH is a tertiary care facility with 
adult and neonatal ICU facilities. Referral from MPMOU to a secondary of tertiary care 
facility occurs antenatally or peri-partum if a pregnancy is considered to be high risk or 
requires advanced care. This could be due to: the presence of specific risk factors, certain 
medical conditions or having a poor obstetric history. 
MPMOU forms part of the Mitchell’s Plain Community Health Centre which serves an 
estimated 1.2 million people which are predominantly “Coloured”. Furthermore 
approximately 24% of community members are unemployed with as many 16% of 
individuals having not completed grade 7 [26]. 
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 Study population 
 
3.3.1 Study participants 
 
Data from the CTG database of pregnant women that attended antenatal care and/or 
delivered at either MPMOU or one of its referral sites (after referral from MPMOU), during 
the period 1 July 2014 – 31 December 2016, will be considered for inclusion in the study. 
The CTG study automatically enrolled all pregnant women upon their first antenatal visit at 
MPMOU or alternatively upon presentation for delivery if they had not received antenatal 
care. Enrollments occurred from 1 February 2014 – 30 June 2016. Individuals were followed 
to delivery up until the end of 2016. In July 2014 the Western Cape Prevention of Mother-to-
Child Transmission of HIV (PMTCT) Clinical Guidelines were updated to recommend an HIV 
test at delivery [22]. For the purposes of this study and maintaining a single policy period 
with regards to HIV testing of pregnant women, only women that enrolled from 1 July 2014 
will be considered for inclusion. 
 
3.3.2 Eligibility criteria 
 
Women will be eligible for inclusion in the study analysis if they: delivered at MPMOU or 
one of its referral sites, MMH, MPDH or GSH between 1 July 2014 and December 2016 with 
a live or still birth pregnancy outcome. Women who attended for delivery at MPMOU or one 
of its referral sites through a basic antenatal clinic (banc) as well as those for whom no 
pregnancy outcome can be found (after cross checking with clinical records) will be excluded 
from the study since we do not have access to complete longitudinal HIV testing data for 
these individuals Without a documented pregnancy outcome and visit data we do not know if 
the pregnancy was sustained or if participants transferred to other (unobserved) facilities and at 
what point they did so. Keeping them in the dataset could result in the underestimation of repeat 
testing completion. That said, it is acknowledged that the testing outcomes for the subset of 
women without recorded pregnancy outcomes may be systematically different from those for 
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whom outcomes are recorded and excluding them from the study could introduce selection bias 
and a slight overestimation of testing completeness.  
 
3.3.3 Sample size 
 
At the time of primary data collection there were approximately 7000 pregnant women 
presenting at the MPMOU yearly of which 30% present through bancs. When excluding 
pregnant women that present through bancs it is anticipated that during the two year 
enrollment period under analysis in this study (1 July 2014 – 30 June 2016) approximately 
9800 pregnant women would have attended antenatal care and/or delivered at MPMOU or 
one of its referral sites.  
 
 Research procedures and data collection methods 
 
This study will use data collected as part of the CTG study. Data for the CTG study were 
collected prospectively up until December 2016. Point of care rapid HIV tests i.e. antibody 
assays were performed by community care workers as part of routine ANC services and by 
nurses in the labour ward of MPMOU and the labour/post-natal ward of the hospitals. Data 
elements from antenatal HIV testing registers, labour ward HIV PMTCT registers and 
delivery registers as well as HIV-associated laboratory and ART data were digitized and 
consolidated to form the PMTCT e-register. Data linkage fields included WC unique patient 
identifiers (“folder numbers”), birth dates and delivery dates. Study enrollments were 
stopped from 1 July 2016. 
Maternal PMTCT episode and visit test data for the period 1 July 2014 – 31 December 2016 
will be extracted from the database of the CTG cohort for the purposes of this study (see 
Table 1 for variables of interest). No patient contact or involvement is required for this study 
and data will be de-identified prior to analysis. 
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 Data management 
 
Data extracted from the password-protected CTG database will be secured as an encrypted 
and password protected electronic file and stored within the UCT firewall-protected SQL 
server. In addition, the dataset and study information will be backed up on a password 
protected hard drive. Data cleaning will include: filtering the dataset according to the 
studies inclusion/exclusion criteria; identifying and deleting across-all-variable duplicates; 
and following up of logic violations and missing observations/outcomes with original clinical 
records. All data queries, responses and edits will be recorded. 
Maternal episode data will be merged with maternal visit test data using folder number 
identifiers resulting in a database of initially HIV unknown/negative pregnant women with 
their corresponding HIV testing data throughout their pregnancy as well as women who 
were known HIV-positive at the time of enrollment. Once merging is complete each 
participant will be allocated a unique study identifier and all prior identifiers will be 
removed from the dataset. 
 
 List and definition of variables 
 
A list of the variables to form part of data analysis, and their respective classifications and 
definitions, is shown in Table 1.  
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Table 1. Variable list 
Variable Classification Definition 
Age  Continuous: numerical (years) Mother’s age at time of enrollment. 
Enrollment facility Categorical: nominal (MPMOU/ 
MPDH/MMH/GSH) 
Facility at which participant first visited 
for antenatal test or delivery. 
Year of enrollment Categorical: ordinal (2014/2015/2016) Year in which participant enrolled. 
Delivery facility Categorical: nominal (MPMOU/ 
MPDH/MMH/GSH) 
Facility at which participant delivered. 
Mode of delivery Categorical: nominal 
(vaginal/assisted/caesarian) 
Mode by which baby was delivered. 
Birth outcome Categorical: binary (alive/stillborn) Birth outcome of infant. 
Premature birth Categorical: binary (yes/no) Birth <37 weeks gestation.* 
Antenatal care 
 
Categorical: binary (yes/no) Whether or not participant presented 
for antenatal testing before delivery. 
Gestational age at 
first test 
Continuous: numerical (weeks) A measure of the foetal age when the 
participant received her first HIV test. 
Time from “booking” 
to delivery 
Continuous: numerical (weeks)  Number of weeks before delivery at 
which participant “booked”. 
Number of tests Discrete: numerical (1, 2, 3…) Number of HIV tests received by 
participant from “booking” up until 
delivery/immediately post-partum. 
Time of HIV diagnosis Categorical: nominal (at enrollment, 
after enrollment, never) 
The point at which participant was 
diagnosed HIV+ from enrollment until 
delivery. 
Seroconversion † Categorical: binary (yes/no) Whether or not participant 
seroconverted between enrollment and 
delivery. 
Gravidity Discrete: numerical (1, 2, 3…) The number of pregnancies a 
participant has had in lifetime. 
Second pregnancy Categorical: binary (yes/no) Whether or not participant had a 
second pregnancy during the study 
period.  
Parity Discrete: numerical (1, 2, 3…) The number of live births participant 
has had in lifetime. 
*Gestational ages as documented in the delivery registers. 
† Seroconversion – The transition from a negative HIV antibody test result to a positive HIV antibody test result 
due to the production of a detectable quantity of HIV antibodies by an individual [21].  
MPMOU: Mitchell’s Plain Midwife Obstetric Unit; MPDH: Mitchell’s Plain District Hospital; MMH: Mowbray 
Maternity Hospital; GSH: Groote Schuur Hospital 
 
Outcome variables 
1. Missed maternal HIV testing 
No HIV testing (i) at all or (ii) during one or more of the recommended testing windows 
(at “booking” (< 20 weeks); 32 -34 weeks; date of delivery ± 5 days), and delivered at 
MPMOU or one of its referral facilities.  
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2.  HIV diagnoses 
Diagnosis as HIV-positive, either on date of enrollment or at any subsequent testing 
visits. 
The study period for each woman will commence at initial antenatal “booking” and will end 
5 days after delivery, allowing leeway time for delivery testing. Among “un-booked” women 
the study will commence on date of delivery. Women with an unknown pregnancy outcome 
will be excluded. 
 
 Data Analysis 
 
Data analysis for this study will be carried-out using Stata version 13.0 (Stata Corporation, 
College Station, Texas, USA). 
Descriptive statistics will be conducted using means and confidence intervals (CI) for 
normally distributed continuous variables, medians and interquartile-ranges (IQR) for non-
normally distributed continuous variables, and proportions for categorical variables.  
Overall testing completion as well as testing completion within each recommended testing 
window will be examined using frequency tables to describe the proportion of missed tests 
among eligible participants at each time point.  
Frequency tables will also be used to describe HIV prevalence and incidence at each time 
point. 
Differences will be assessed using the two-sample t-test (normally distributed data) or the 
Wilcoxon rank-sum (non-normally distributed data) for numerical data and the χ2 or Fishers 
Exact test for categorical data. Significance will be determined at a level of 0.05. 
As testing outcomes are binary (tested/not tested) multiple logistic regression models will 
be used to determine potential predictors of not testing: at all, at “booking”, at delivery, and 
missing one of the three recommended tests.  
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Multivariable models will incorporate covariates (age at enrolment, gravidity, & year of 
enrolment) that are decided on a priori based on them being known or suspected risk 
factors for the outcome of interest. Other variables will be sequentially added to the model 
based on univariable analysis significance and retained if they are either significantly 
associated with the outcome of interest (p<0.05) or alter the odds ratios of other variables 
in the multivariable model by ≥10%. Model outputs will be presented as odds ratios with 
95% confidence intervals (CI). 
4. Ethical considerations 
 
 Ethical Approval 
 
Ethics approval for the larger CTG study has already been received from both the University 
of Cape Town Human Research Ethics Committee (UCT-HREC) (HREC: 145/2013; Appendix 3) 
and the Provincial Government of the Western Cape (PGWC) Department of Health 
Research (RP063/2013; Appendix 3). 
Ethical approval for this proposed CTG sub-analysis study will be sought from the UCT-HREC. 
The study will be conducted in accordance with the protocol, the Declaration of Helsinki and 
the local rules and ethical regulations of South Africa.  
 
 Risks and benefits 
 
This study is considered to be minimal risk. The sub-study is a secondary analysis of existing 
CTG data. The only risk to study participants is breaching of patient confidentiality. 
However, significant precautions will be taken throughout the study process to protect 
patient confidentiality. Identifiable data linkage fields included in the data set are: Folder 
numbers, birth dates and delivery dates. The inclusion of folder numbers is essential for the 
merging of episode and visit test data, but these will be removed from the dataset once the 
merge is complete. All analysis will be done on anonymized data. 
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There will be no direct benefits to participants of this study; however, the proposed study 
could potentially benefit participants during future pregnancies. The study will still provide 
insight into the individual level PMTCT HIV testing coverage gaps among pregnant HIV 
women thereby enabling targeted future interventions for the closure of these gaps. 
Furthermore, knowledge of risk factors found to be associated with testing incompletion 
will assist with the antenatal identification of women who, although HIV-negative, may 
require additional support throughout the PMTCT continuum. 
 
 Informed Consent 
 
The larger CTG study was granted a waiver of informed consent for the construction of the 
e-register as all data had already collected routinely by health services. No participant 
recruitment was required. A single trained data clerk, who had completed the online NIH 
Protection of Human Subjects training, was responsible for entering data onto the current 
provincial medical records platform. The primary dataset was thus collected in an ethical 
manner. 
No additional participant recruitment is required for this sub-analysis. 
 
 Privacy and confidentiality 
 
All the necessary steps will be taken to ensure the confidentiality of study participants. The 
dataset will be anonymized by removing participant identifiers once the merge of episode 
and visit test data is complete and allocating unique identification numbers to participants.  
The dataset to be analyzed will be password protected and securely stored on the UCT 
firewall-protected SQL server housed within the CIDER offices. In addition, the dataset will 
be backed up on a password encrypted hard drive. Any data transfer will be secured by 
password protected encryption and compression with the password being communicated 
telephonically or in person. The dataset will only be accessible to authorized researchers. 
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 Involvement of vulnerable persons   
 
This study involves the analysis of data on pregnant women and therefore a vulnerable 
population.  The inclusion of data from this study group is however essential as they are the 
group of interest to whom all study findings will be inferred. Nonetheless, measures are in 
place to protect these participants. 
 
 Research related compensation and insurance  
 
As this project does not involve participant recruitment there will be no compensation or 
potential injury to study participants. 
5. Dissemination of Findings 
 
The research findings obtained from the proposed study will be submitted in partial 
fulfilment of the requirements for the Master of Public Health (Epidemiology and 
Biostatistics) degree at the University of Cape Town. Furthermore, the findings will be 
submitted to an appropriate peer review journal for publication. A report or presentation of 
the findings will be offered to all interested stakeholders. 
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6. Logistics 
 
 Timetable 
 
Timetable for proposed study: 2018 - 2019 
 
N
o
ve
m
b
er
  
D
ec
em
b
er
 
 Ja
n
u
ar
y 
 
 Fe
b
ru
ar
y 
Departmental and ethical 
approval X   
 
Clean, check and merge 
datasets X X  
 
Data analysis  X   
Writing of manuscript  X X  
Submission of dissertation   X  
Dissemination of findings    X 
 
 Budget 
 
Data for the proposed study has already been collected therefore no further costs will be 
incurred. 
7. Appendices 
 
 Appendix 1 
Supplementary methods 
 Appendix 3 
Closing the Gaps in PMTCT Programme Coverage, Early Infant Diagnosis and Treatment 
(CTG) 
 Appendix 4 
• UCT-HREC (HREC: 145/2013) 
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• PGWC Health Research approval (RP063/2013) 
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SECTION B: LITERATURE REVIEW 
 
1. Background 
 
In 2011, 21 sub-Saharan Africa (SSA) countries including South Africa, ranked globally as 
having the highest number of HIV-positive pregnant women, were prioritized as part of the 
Global Plan aimed to keep mothers alive and eliminate incident HIV infections among 
children by 2015 – the “Global Plan” [1].  
Shortly after the launch of the Global Plan, the World Health Organization (WHO) 
introduced the option of the initiation of immediate lifelong triple ART for all HIV-positive 
pregnant women (Option B+) in 2012 [2]. By 2015, Option B+ was being offered by all the 
Global Plan countries except Nigeria [3]. Consequently, great progress has been made in 
reducing mother-to-child transmission (MTCT) in the 21 priority countries [1,3]. However, 
challenges remain in achieving the virtual elimination of MTCT [1,4,5].  
HIV testing of pregnant women is an essential step in the prevention of mother-to-child 
transmission (PMTCT) [6]. It is the point of entry to the care and treatment necessary to 
optimize the prevention of transmission. Without universal HIV testing during pregnancy, 
virtual MTCT elimination cannot be achieved [7,8]. In addition, evidence suggests that 
women are at an increased risk of HIV infection during pregnancy and furthermore, acute 
rather than chronic HIV infection leads to an increased risk of MTCT [9–14]. This has placed 
emphasis on the importance not only of a single HIV test at first antenatal visit, but also of 
repeat HIV testing throughout pregnancy, particularly testing during late pregnancy and/or 
at delivery [11,14,15]. Owing to the success of Option B+ at initiating ART in women 
identified as HIV-infected either prior to or at their first antenatal visit,  MTCT may now be 
more likely to occur in pregnant women who test HIV-negative at their first antenatal care 
(ANC) visit and seroconvert thereafter (antenatally or postnatally) [14]. The WHO 
recommends that pregnant women from areas with a generalized HIV epidemic receive HIV 
retesting in the third trimester, and at delivery, or directly thereafter [6,16]. 
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This literature review aims to inform the proposed study: A longitudinal analysis of the 
completeness of maternal HIV testing, including repeat testing, during pregnancy, and the 
predictors thereof, in Mitchell’s Plain, Cape Town, by critically evaluating the available 
evidence on antenatal and repeat/late pregnancy HIV testing in SSA countries since the 
2010 amendment of the WHO guidelines to recommend repeat antenatal HIV testing in 
areas with generalized HIV epidemic settings.  
2. Objectives 
 
The main objective of the review is to appraise all published quantitative studies that report 
on antenatal, repeat or late pregnancy HIV testing coverage within SSA countries, for the 
period 2010 – June 2018.  
The specific objectives of the review are to: 
 Describe the antenatal and repeat/late pregnancy HIV testing coverage within 
different SSA countries and to report on the HIV prevalence and/or incidence at 
respective testing time-points. 
 Describe the feasibility and acceptability of repeat/late pregnancy testing within 
different SSA countries. 
 Describe identified predictors of testing completeness within different SSA countries. 
 Identify areas of antenatal and repeat/late pregnancy testing that require further 
research. 
3. Search Methods 
 
PubMed and Google scholar were searched for sources relevant to this literature review. 
Search terms included HIV, PMTCT, antenatal/repeat testing and SSA countries (see Box 1 
for variations) with the search being restricted to English publications. The references of 
included studies were searched for additional relevant sources. 
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Publications were considered for inclusion if they were either systematic reviews, 
experimental or observational studies conducted during the period 2010 – present (June 
2018). 2010 was selected as the starting point as this is when the WHO amended their 
recommendations to include repeat antenatal HIV testing [16]. Reports were only included 
if the study 1) was conducted in a SSA country and 2) included antenatal or repeat/late 
pregnancy HIV testing coverage as an outcome of interest. Tables 1 and 2 summarize the 
included studies. 
To contextualize the review of included studies I also drew on other studies around HIV 
testing coverage that may not have met the inclusion criteria for this review. 
Box 1. Search strategy – term variations 
4. Summary of the literature 
 
4.1 Antenatal HIV testing 
 
As the point of entry to the HIV services offered to women as part of PMTCT, antenatal HIV 
testing is a critical step in the pathway to the elimination of MTCT [17].  
In 2012 the WHO introduced Option B+ which recommended immediate initiation of 
lifelong triple ART for HIV-positive pregnant women irrespective of their CD4 count [2]. The 
HIV: "HIV"[Mesh]) OR HIV, Human Immune Deficiency Virus, Human immunodeficiency virus 
PMTCT: Mother-to-Child Transmission of HIV, Prevention of Mother- to- Child Transmission of 
HIV, Vertical Transmission, Vertical Transmission of HIV 
Antenatal/repeat testing: repeat HIV testing, delivery testing, delivery HIV testing, testing during 
late pregnancy, maternal testing, maternal HIV testing, antenatal testing, antenatal HIV testing, 
testing during labour, retesting 
Sub-Saharan Africa: sub-Sahara* Africa*, Angola, Benin, Botswana, Burkina Faso, Burundi, 
Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Democratic Republic of 
Congo, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, Madagascar, 
Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Principe, Rwanda, 
Sao Tome, Senegal, Seychelles,  Sierra Leone, Somalia, South Sudan, South Africa, Swaziland, 
Tanzania, Togo, Uganda, Zambia, Zimbabwe 
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rationale for Option B+ is that through a high detection rate of HIV-positive pregnant 
women there would be optimal effective treatment coverage therefore offering not only 
protection against MTCT amongst these women during pregnancy, delivery, breastfeeding 
and any other subsequent pregnancies during their lifetime, but also a positive impact on 
the mothers’ health [18]. The introduction of Option B+ has significantly reduced MTCT 
globally, however its success relies heavily on antenatal HIV testing for the detection of HIV-
positive mothers [1,3,16,19].  
The benefits of antenatal HIV testing are not limited to women who are HIV-positive. 
Testing and counselling early during pregnancy can provide HIV-negative women with the 
necessary guidance towards the prevention of HIV acquisition [20]. This is particularly 
important as pregnant women are at increased risk of HIV infection and, if infected during 
pregnancy, of transmitting virus to their infants [9–14]. In addition, women who present 
early for HIV testing and who are HIV-negative are eligible for a second testing opportunity 
later in pregnancy, in the third trimester of pregnancy or at delivery [16]. This enables the 
early detection and treatment initiation of women who have seroconverted during 
pregnancy. 
Current WHO recommendations are that provider initiated testing and counselling (PITC) for 
HIV should form a routine component of ANC services in high HIV prevalence settings [20]. 
Furthermore PITC should be offered to pregnant women at their first ANC visit which should 
ideally be in the first trimester, before 12 weeks gestation [21]. It should however be noted 
that it is not common for pregnant women to present <12 weeks gestation in SSA [22]. 
There has also been an observed increase in antenatal HIV testing outside of health care 
facilities through community outreach programmes such as home-based testing [16]. 
In this literature search 13 studies reporting on antenatal HIV testing coverage among 
pregnant women in SSA countries, published post 2010, were identified. Of these studies 10 
[23–32] were conducted in the period from 2010 onwards while the remaining 3 studies 
[33–35] included data that was either collected before and after 2010 or during a period 
that included 2010. All 13 studies were included in this review. The studies were conducted 
in: Zimbabwe [26,33], Ethiopia [27,29], Nigeria [25,28,30], Congo [25], Mozambique [25], 
Uganda [25], Ghana [31], Malawi [23,35], Kenya [34] and Tanzania [24,32]. Study types 
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included: 6 cross-sectional [24,25,27–29,33], 2 quasi-experimental [30,35], 1 prospective 
cohort [32], 3 retrospective cohort [23,26,34] and 1 retrospective programme-data review 
[31]. Study sample sizes ranged from 1579 – 2 215 090 pregnant women. 
 
Antenatal HIV testing proportions and HIV prevalence 
 
In this review thirteen studies in 10 different SSA countries reported on antenatal HIV 
testing proportions which ranged from 46% in Congo [25] to 99.96% in Nigeria [28].   
 
4.1.1 HIV testing in routine care settings 
 
Although The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that in 
2013 globally only 46% of pregnant women tested for HIV, non-implementation studies (i.e. 
studies of routine care programmes) across SSA have shown testing proportions ranging 
from 46% – 85% [23,25,36]. In Zimbabwe a cross-sectional study utilizing data from the 
2010/2011 Zimbabwe Demographic and Health Survey (ZDHS) found 60% of pregnant 
women received antenatal HIV testing, an improvement from the 29% observed in the 
2005/2006 ZDHS [33]. More recently Dzangare et al. showed, using routine care data, that 
following the implementation of Option B+ the HIV testing proportion, among women in 
two rural districts in Zimbabwe who registered or presented in ANC, labour or while 
breastfeeding, was 81%, with HIV prevalence of 7% in those tested. Unfortunately the 
proportion of women testing in ANC was not distinguished from those presenting at other 
timepoints, but 76% of women presented to ANC and the proportion tested amongst the 
20% of women presenting in labour was low [26], suggesting ANC testing coverage >81%. In 
Ghana, a large data review on 2 215 090 ANC attendees countrywide revealed that the HIV 
testing proportion decreased annually from 83% in 2011 to 75% in 2013, with 487 725 (22%) 
ANC attendees missing testing opportunities during the 2011 -2013 period. HIV prevalence 
amongst women receiving ANC ranged between 0.3% - 3% across regions and years, but 
overall a decline over time was noted [31]. Studies in North-West and North Ethiopia 
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respectively found 81% and 67% ANC HIV testing proportions among pregnant women in 
their studies [27,29]. Studies conducted on 2011 - 2013 national survey data reported HIV 
testing proportions of 76% in Tanzania [24], 82% in Uganda [25], 69% in Mozambique [25], 
46% in Congo [25], and 54% in Nigeria [25]. 
Even though relatively high antenatal HIV testing proportions (>80%) have been observed in 
several SSA countries since 2010, this remains below the minimal 90% that would be 
required to ensure that 90% of HIV-positive women have access to ART [7]. Given that 
antenatal HIV testing is the entry point to the PMTCT programme and that the failure of 
ANC HIV positivity detection is estimated to account for up to 54% of MTCT in resource-
limited settings, it is concerning that testing proportions below 70% were recorded in 5 of 
the above countries [37]. It should however be noted that the studies in which lowest 
antenatal testing coverages were observed were based on Demographic and Health Survey 
(DHS) data from respective countries [25,33]. Study eligibility required women to have been 
pregnant within 5 years preceding the surveys and the surveys rely on self-report, which 
could have led to recall/reporting bias, limiting the accuracy of study results. Furthermore, 
data for these studies were collected between 2010 and 2013 and may therefore not be 
truly representative of the current coverage of HIV testing in the respective countries 
[25,33]. On the other hand studies on women attending health care facilities do not account 
for pregnant women a) attending the private sector and b) who do not attend ANC and/or 
deliver at home [26,27,29,31]. The HIV testing completion observed in one region of a 
country is also not necessarily generalizable to the country as a whole. This was 
demonstrated by the studies in North-West and North Ethiopia by Abtew et al. and Alemu 
et al. respectively finding different ANC HIV testing proportions (81% and 67%) [27,29]. 
Studies conducted after Option B+ implementation showed that although the uptake of 
antenatal HIV testing was high and there were overall improvements in the PMTCT 
continuum, challenges with HIV testing remained [23,26,32,35]. In Malawi, Kim et al. and 
Tenthani et al. observed antenatal testing proportions of 88% and 86% respectively in 
different regions post Option B+ implementation [23,35]. HIV prevalence among newly 
tested women was 7% in the study by Kim et al. [35]. Both studies used historical control 
groups to evaluate the impact of Option B+ on HIV testing proportions. Kim et al. observed a 
significant drop in testing proportions while a small, but non-significant increase was seen 
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by Tenthani et al. [23,35]. It is thought that the unexpected results, i.e. the drop in testing 
proportions and failure to reach 90% testing completion, seen post the introduction of 
Option B+ are reflective of challenges at the facility level - in particular a shortage of test kits 
during the study interval [23,35]. A study in Tanzania found that implementing Option B+ 
through an integrated service delivery One Stop Clinic resulted in a remarkable 94% HIV 
testing proportion with 3% of women testing positive. They however reported that 20% of 
women arrived in labour with an unknown HIV status which is concerning as either they are 
not attending ANC or there are testing gaps at other facilities [32]. While the above studies 
are mostly reassuring as they indicate high maternal HIV testing coverage following 
implementation of Option B+, which suggests promise for the success of B+ in PMTCT [5,16],  
the large proportion of women presenting in labour with an unknown HIV status means that 
ANC testing proportions overestimate the true proportion of all pregnant women tested. 
This introduces the importance of non-traditional setting antenatal HIV testing i.e. testing 
settings that would not normally form part of conventional routine care e.g. testing outside 
of healthcare facilities [16].  
 
4.1.2 HIV testing in non-traditional settings 
 
There is evidence that the implementation and/or integration of antenatal HIV testing into 
non-traditional testing settings provides an opportunity to identify and test pregnant 
women who don’t attend ANC [28,30,32,34]. Akinyele et al. investigated the integration of 
opt-out HIV testing into maternal, newborn, and child health (MNCH) weeks in Nigeria. They 
found that 99.96% of women attending these weeks accepted testing of whom 31% had not 
attended ANC. Among those who hadn’t attended ANC, 62% had never been tested for HIV. 
The HIV prevalence among all women being tested was 2%, and among those never 
previously tested was 5% [28]. Using a quasi-experimental design Chiboza et al. evaluated 
the integration of traditional birth attendants in primary health care (PHC) centers (the 
“TAP-In” model) in Nigeria. After implementation of TAP-In the intervention group 
contributed three times the number of pregnant women receiving HIV counselling and 
testing (HCT) compared to the control group [30]. However, this study did not report 
proportions of women tested and so comparison of the control and intervention groups is 
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not possible. In Kenya in a home-based HCT (HBCT) programme, 97% of pregnant women 
accepted testing of whom 41% had not attended ANC. The overall HIV prevalence among 
tested women was 7%, but interestingly it was 9% among non-ANC attenders compared to 
5% among ANC attenders. A substantial 241(3.3%) women were newly diagnosed as HIV-
positive [34]. As mentioned above, Gamell et al. reported 94% ANC testing coverage at a 
One Stop clinic in Tanzania integrating all maternal and pediatric services. In this study 3% of 
women were newly diagnosed as HIV-positive [32].  
The above studies illustrate the potential for closing the access-related gaps in antenatal 
testing using non-traditional testing settings. Importantly the HIV testing proportions 
reported were well over 90% and a large proportion of women who hadn’t attended ANC 
were identified which enabled them access to the PMTCT programme. The observation that 
women who don’t attend ANC are more likely to test positive compared to those that do 
attend ANC highlights the importance of targeting these women through non-traditional 
interventions to tackle the elimination of MTCT [28,34]. Further investigations need to be 
conducted to determine the cost effectiveness of these interventions [28]. 
In summary, the literature indicates that there is a wide range of antenatal HIV testing 
coverage proportions across SSA, but proportions are mostly below the minimal 90% 
required to ensure that 90% of HIV-positive women have access to ART [7,24–27,29,31,33]. 
The uptake of testing post Option B+ implementation was high (>80%) despite facility-level 
challenges [23,26,32,35]. This is a promising start to the optimization of the effectiveness of 
Option B+. There are however a large proportion of women who do not attend ANC, some 
of whom present in labour with unknown HIV status and others that deliver at home 
[28,31,32,34]. Furthermore, women who don’t attend ANC are more likely to be HIV-
positive [34,38]. The integration of antenatal HIV testing into non-traditional testing 
settings/programmes such as MNCH weeks, TAP-In and HBCT has shown to be effective in 
accessing women who don’t attend ANC, thereby increasing antenatal HIV testing among 
pregnant women [28,30,32,34]. The HIV prevalence among women testing emphasizes the 
importance of antenatal testing in eliminating MTCT [26,34,35]. 
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4.2 Repeat or late pregnancy HIV testing 
 
There are numerous reasons for the importance of repeat/late pregnancy HIV testing. 
Women are at an increased risk of seroconverting during pregnancy and those who do 
seroconvert are more likely to transmit infection [9–11,14]. Moreover, HIV is most 
commonly diagnosed using a rapid antibody test which fails to accurately diagnose HIV 
during the so-called “window period” [39]. Given that it can take up to 3 months to produce 
detectable antibody levels women should have the opportunity to test again later in 
pregnancy or at delivery [40]. Furthermore, in many resource limited settings pregnant 
women present to healthcare facilities for the first time during labour with an unknown HIV 
status [41–43]. Testing during labour enables HIV-positive mothers with previously unknown 
HIV status and their exposed infants to receive the necessary HIV care to reduce the risk of 
transmission and prioritize early infant diagnosis [42,44]. Infections only diagnosed late in 
pregnancy or during labour could also be as a result of incorrect antenatal test results [42]. 
Considering the importance of repeat/late pregnancy testing, labour room HIV testing was 
recommended by the Center for Disease Control and Prevention (CDC) in 2004 and was 
followed by the WHO 2010 recommendation that pregnant women from settings with 
generalized HIV epidemics receive HIV retesting in either the third trimester, at delivery, or 
directly thereafter [16,19]. 
For the 21 SSA countries tasked with the Global Plan of keeping mothers alive and 
eliminating incident HIV infections among children, reducing MTCT by laying a stable 
repeat/late pregnancy testing foundation has been essential. In this literature search 7 
studies, published from 2010 onwards, that reported on repeat/late pregnancy testing 
coverage were identified. Of these, only 3 studies were conducted from 2010 onwards [45–
47]. Given the limited availability of studies fulfilling the set selection criteria the other 4 
studies were included in this review as 3 of them [41,42,48] had been conducted after the 
CDC recommended HIV testing in labour in 2004 and the remaining one [49], did not report 
on the study period but was published in 2014. Among these studies, 4 [41,42,45,48] were 
implementation studies in the sense that repeat/late pregnancy HIV testing was offered as 
part of the study protocol while the other 3 studies were conducted in settings where 
repeat testing had already been implemented in routine care [46,47,49]. The studies were 
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conducted in: Swaziland [42], Nigeria [41,48], Togo [45], Zambia [47,49] and Kenya [46]. 
Sample sizes in these studies ranged from 104 – 2444 pregnant women. 
 
Repeat or late pregnancy HIV testing proportions and HIV positivity. 
 
Repeat/late pregnancy HIV testing implementation studies around SSA report that high 
coverage of HIV testing is feasible when offered to women in labour in countries were 
retesting is not routinely offered [41,45,48]. A cross sectional study conducted in a South-
West Nigerian hospital reported that 87% of pregnant women presenting for the first time 
during labour accepted HIV testing. The HIV prevalence amongst these women was 7%, 
higher than the national estimated HIV prevalence of 5% around that time [41,50]. In Togo, 
92% of pregnant women admitted to hospital during pregnancy were receptive of being HIV 
tested. Seventy percent of individuals testing in labour had previously tested during ANC 
and were therefore repeat tested. HIV prevalence among women testing in labour was 9% 
compared to Togo’s estimated national HIV prevalence of 3% at the end of 2009 [45,51].  
Onakewhor et al. found that in a Southern Nigerian hospital 96% of women who tested HIV-
negative at an antenatal visit 12 weeks prior to delivery were tested again during labour 
with 0.3% of women seroconverting in this period [48].  
In contrast to the high acceptance of in-labour HIV testing in the study setting in those 
countries where repeat testing is not routinely offered, there is evidence that repeat testing 
coverage is poor in those programmes where repeat testing has already been implemented 
as part of routine care [47,49]. In Zambia, Hemelaar et al. examined repeat HIV testing 
coverage among women who delivered at a rural district hospital [47]. After delivery 47% of 
all women had an updated HIV status: 8% were HIV-positive and 39% had tested HIV-
negative recently (< 3 months). Out of those with an updated HIV-negative status 63% (25% 
of all women) had been retested during pregnancy/delivery. Moreover, 53% of women 
missed opportunities for repeat testing by leaving hospital after delivery with an unclear HIV 
status either because they were last tested HIV-negative more than three months before 
delivery or because they never tested during pregnancy and delivery. Among those who 
were HIV-positive almost half (48%) were newly diagnosed at their initial test in pregnancy 
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(2 in first trimester, 9 in second trimester, 1 at delivery). No seroconversions were reported 
[47]. Another Zambian study conducted in a postnatal clinic in Lusaka reported that only 
36% of women had been retested antenatally [49]. The low repeat testing  coverage may be 
partly due to the hesitation of health facility staff to counsel and test patients as well as a 
lack of awareness of the need for repeat testing on the part of pregnant women [42,47,49]. 
In line with this, a quasi-experimental intervention study conducted in Swaziland found that 
a targeted one-day training programme for midwife-nurses significantly increased the 
uptake of repeat testing by women at delivery [42]. At intervention sites 45% of previously 
tested HIV-negative women and 96% of women with unknown status were tested in 
comparison to 14% and 65% coverage at control sites. Amongst those testing with unknown 
HIV status the HIV prevalence was 35% and 45% at the intervention and control sites 
respectively. The seroconversion rate among those whom enrolled with a HIV-negative 
status was 4% across all sites [42]. These results emphasize the importance in health 
workers a) understanding the increased risk of seroconversion during pregnancy and b) 
having sufficient training to optimally implement the available PMTCT guidelines such as 
repeat testing. 
Four of the above studies were conducted in single hospitals which were referral centers 
[41,45,47,48]. Many women referred to these labour wards were “unbooked” and 
presented as emergency cases. Onakewhor et al. limited their study to women who had 
tested negative at “booking”, but both Bello et al. and Ekouevi et al. had a large proportion 
of “unbooked” women in their studies [41,45,48]. This is a study limitation as the individuals 
included are representative of a very specific population of women who have not accessed 
ANC and the observed results may therefore not be generalizable to the entire population 
of pregnant women within the respective countries. Another limit to the generalizability of 
the observed study results is that in the three above mentioned countries the estimated 
percentage of births attended by skilled personnel, inside and outside health facilities, 
ranges from 43% – 63% [52], hence HIV testing coverage at delivery for all births may be 
considerably lower. Although the aforementioned studies [41,42,45,47–49] provide insight 
to the acceptability and feasibility of repeat or labour HIV testing, very little information is 
provided on the uptake and adherence of pregnant women to HIV repeat testing in 
countries where it has already been implemented into the PMTCT guidelines.  
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The PMTCT care continuum is implemented sequentially throughout pregnancy and may 
involve multiple service providers, ultimately resulting in the collection of data across 
facilities and at different steps throughout the continuum [8,53]. This approach accounts for 
aggregate reporting of PMTCT coverage with no linkage across the different platforms and 
consequently no tracking of an individual pregnant woman’s progress through the care 
continuum [54]. Reporting on aggregate level data is likely to result in an overestimation of 
the true coverage (e.g. proportion of women ever HIV tested during pregnancy or 
proportion of women tested in third trimester) compared to when taking individual level 
uptake and adherence into account (e.g. proportion of women undergoing all 
recommended HIV tests). The utilization of longitudinal maternal PMTCT data enables a 
more accurate estimation of repeat testing coverage [55]. To date only one study has been 
conducted using longitudinal antenatal data. In 2017 Rogers et al. reported a significant 
increase in HIV retesting among pregnant women in Kenya, from less than 1% in 2011 to 
almost 45% in 2013, since the implementation of retesting guidelines in 2012 [46]. The 
study was conducted in a large hospital in rural South-West Kenya and made use of 
abstracted data from paper ANC registers. Among study participants, the HIV prevalence at 
delivery was 26%, higher than the already substantial 15% recorded for that area of Kenya 
[56]. Seven percent of individuals were newly diagnosed HIV-positive with seroconversion 
from the first to repeat test being 2% among initially HIV-negative women. Despite the 
improved repeat HIV testing a large proportion (58%) of women had missed opportunities 
for repeat testing [46]. 
Overall, the literature suggests that in SSA repeat or late pregnancy HIV testing is feasible 
and well accepted among pregnant women attending referral hospitals in settings where 
repeat testing has not yet been adopted by PMTCT guidelines [41,45,48]. Settings that have 
included repeat HIV testing in guidelines have experienced an increase in provider initiated 
repeat testing, however major gaps remain [46,47]. Targeted training of healthcare 
professionals can improve the uptake of repeat testing [42]. It is concerning that in most of 
these settings there is a large proportion (9% - 34%) of women who present in labour with 
an unknown HIV status and as a result many individuals are first diagnosed with HIV at 
delivery [41,42,45]. Furthermore, there are instances where individuals are ineligible for 
retesting late in pregnancy as their first antenatal visit was less than 3 months before 
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delivery [47]. These missed opportunities in HIV testing delay essential timely HIV treatment 
for pregnant women who were unknowingly HIV-positive or who seroconverted, their 
infants and their partners [26].  
 
4.3 Predictors of HIV testing completeness  
 
Complete HIV testing is the first step to a successful PMTCT programme and ultimately the 
virtual elimination of MTCT [16,19]. Targeted interventions and their successful 
implementation are required to close identified gaps in the testing continuum. The 
identification of predictors of testing completeness will go a long way in directing 
intervention planning. 
 
4.3.1 Antenatal or early pregnancy HIV testing 
 
A variety of individual as well as health system predictors of receiving an antenatal HIV test 
have been identified [23–29,33,34,57]. The individual level variables commonly associated 
with antenatal HIV testing across studies included: age, education, socio-economic status, 
number of ANC visits, parity, and HIV/MTCT knowledge. 
Socio-demographic factors observed to be associated with antenatal HIV testing included 
higher education [24,25,29,33,34], higher socio-economic status [24,25,33,34], lower parity 
[26,29,33] and being unmarried [34]. Women of younger age were most commonly 
reported to be more likely to test antenatally compared to older women [25,28,29,33], 
although two studies found that that testing likelihood increased with maternal age [23,24].  
Other individual-level factors associated with greater likelihood of antenatal HIV testing 
included: attending more than one ANC visit [23], “booking” at health facilities before 
labour [26], lack of perception of HIV/AIDS stigmatization [25,27,29,33], knowledge of MTCT 
and PMTCT [25,29], and receiving ANC counselling on HIV testing [24].  
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Evidence shows that community and health system related factors also effect the uptake of 
ANC HIV testing [25,58]. Gunn et al. found that women who didn’t experience difficulty 
accessing healthcare facilities were more likely to test antenatally than those that struggled 
to access facilities. Furthermore they saw that being attended to by a skilled ANC provider 
was significantly associated with being tested for HIV [25]. Some studies identified urban 
residence to predict antenatal testing [25,29], however one study found rural residence to 
be a predictor [27]. This was thought to be context-specific and linked to understanding and 
education among the rural women [27]. Lack of HIV/AIDS stigmatization at the community-
level was also positively associated with ANC HIV testing [33]. 
 
4.3.2 Repeat or late pregnancy HIV testing 
 
Multiple individual-level factors have been shown to be associated with repeat or late 
pregnancy HIV testing [41,44,45,48,49,59,60]. There however appears to be very little 
coherence between studies with regards to reported predictors. For example, some studies 
have found that those of younger maternal age were more likely to accept repeat/labour 
HIV testing [44,59,60] whereas, Onakwhore et al. reported that maternal age ≥25 years was 
significantly associated with repeat testing (OR: 5.0; P<0.02 (no CI provided)) [48]. The study 
conducted by Onakwhore et al. differed from the other three studies in that the study 
population was specifically women of known HIV-negative status. Furthermore their <25-
year age group of women comprised only 10% of study participants and may therefore not 
have been representative of this age category in the general population. 
Another characteristic with conflicting results on association with repeat/late pregnancy HIV 
testing is education level. Onakwhore et al. reported that secondary and post-secondary 
education were significantly associated with retesting acceptance (OR: 622.4; P<0.001 (no CI 
provided)) [48]. This result may not be generalizable as only 4% of their study population 
had an education lower than secondary level. Bello et al. on the other hand found that 
those with a higher level of education were less likely to accept HIV testing in labour (OR: 
0.3; CI: 0.1 – 0.7) [41]. These conflicting results may be due to the different study 
populations and outcomes of interest. Onakwhore et al. were studying repeat testing 
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among known HIV-negative women who had received ANC, whereas Bello et al. were 
studying labour testing among women who presented for delivery without prior ANC. 
Although not investigated in the study it is likely that presenting “unbooked” may itself be 
related to having a lower education status. These individuals may then genuinely be more 
interested in knowing their HIV status compared to the higher educated individuals who are 
likely to have specific reasons for not wanting to be tested. Also to note, in addition to only 
studying “unbooked” individuals Bello et al. had a relatively small sample of women (104) 
and may therefore not be representative of the general population of pregnant women in 
Nigeria [41].  
Parity has also been shown to influence acceptance of repeat and labour HIV testing. 
Women in Nigeria with parity ≥1 were more likely to accept HIV retesting (OR: 17.2; P<0.001 
(no CI provided)) [48]. Among pregnant women in Zambia awareness of repeat testing (OR: 
3.9; CI: 2.2 – 6.9); attending ≥5 ANC visits (OR: 3.11; CI: 1.8 – 5.3) and “booking” for delivery 
in the first trimester (OR: 2.4; CI: 1.3 – 4.3) all significantly increased the likelihood of repeat 
testing [49]. 
Only a single study reported on the predictors of repeat HIV testing in settings were repeat 
testing guidelines had been implemented as part of routine care. In Kenya, Rogers et al. 
observed that among women who received ANC early enough and returned to the clinic, 
deeming them eligible for retesting, the year of pregnancy was significantly associated with 
retesting relative to 2011 (2012 = OR: 22.2, CI: 3.0 – 163.0; 2013 = OR: 63.4, CI: 8.8 – 456.0). 
This confirmed that HIV retesting proportions improved subsequent to the guideline 
updates in 2012. Although not associated with retesting, married women and those of older 
age were more likely to a) attend ANC at an earlier gestation and b) return for follow-up 
visits [46]. Targeting those that don’t fall within these categories could possibly increase the 
number of individuals eligible for repeat testing. 
In all, the literature has highlighted the various potential predictors of HIV testing 
completeness, more specifically related to acceptance of retesting, amongst pregnant 
women in SSA. Unfortunately, due to the limited literature available, factors associated with 
repeat/late pregnancy HIV testing varied in different contexts with some of them being 
contradictory and maybe context-specific. Further research is also required to establish the 
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factors associated with better testing completeness in settings that have implemented 
repeat HIV testing guidelines. 
5 Areas for further research 
 
5.1 Antenatal HIV testing 
 
This review highlights that, despite the acknowledged importance of antenatal HIV testing, a 
range of different antenatal testing proportions, from as low as 46%, have been observed 
across SSA. The data collection periods for the studies considered in this review were 
primarily between 2010 and 2015 and it is therefore unclear how well the results of these 
studies represent the current proportions of HIV testing amongst SSA countries. 
Furthermore, the common use of self-report to determine HIV testing proportion means 
that study results may not reflect true testing proportions due to potential reporting bias. In 
addition, when assessing ANC HIV testing coverage studies generally didn’t consider the 
large proportion of women that do not attend ANC. Considering that by 2015 Option B+ was 
offered by all Global Plan countries except for Nigeria, only a handful of studies have 
reported on antenatal HIV testing rates post Option B+ implementation. Good quality, post 
Option B+ implementation studies that incorporate routine data from both ANC services 
and non-traditional testing settings are needed to better understand the current uptake of 
antenatal HIV testing in SSA as well the predictors thereof. Implementation studies are then 
required to assess the effectiveness of testing interventions targeted at those with low HIV 
testing uptake.  
 
5.2 Repeat or late pregnancy HIV testing 
 
This review shows that in general very little research has been conducted on the coverage of 
repeat or late pregnancy HIV testing within SSA. Many of the studies identified were 
implementation studies in settings where repeat HIV testing had not yet been introduced 
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into testing guidelines. Although this provides insight into the acceptability and feasibility of 
repeat or late pregnancy testing, it provides no information on the uptake and adherence of 
routine repeat HIV testing within SSA. Furthermore, the majority of studies reviewed were 
cross-sectional studies conducted in hospitals of which several were referral centers. 
Women are generally referred to hospitals if their pregnancy is considered to be high risk or 
requires advanced care. The results of these studies will therefore be very specific to a 
particular group of women.  
The PMTCT care continuum, including repeat HIV testing, is implemented sequentially 
throughout pregnancy and may involve multiple service providers, ultimately resulting in 
the collection of data across facilities and at different steps throughout the continuum 
[8,53]. As a result, the analysis of longitudinal maternal PMTCT data from linked primary, 
secondary and tertiary care facilities would enable a more accurate estimation of repeat 
testing coverage. Only a single study that made use of longitudinal antenatal data was 
identified. In SSA countries that have implemented repeat HIV testing, there is therefore a 
great need for good quality longitudinal cohort studies that analyze both the completeness 
of repeat testing and HIV incidence at every step of the testing continuum. 
Due to the few studies available on repeat/late pregnancy HIV testing and their lack of 
comparability due to differing contexts there was little coherence amongst predictors of 
repeat testing uptake. The identification of these factors in future studies is important in 
directing targeted intervention studies to improve repeat HIV testing coverage in SSA. 
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Table 1. Summary of studies including antenatal HIV testing as an outcome of interest. 
In-text 
citation 
Author, (year)  Study period Setting Design (sample 
size) 
Population Testing 
proportion 
(antenatal) 
HIV prevalence 
among women 
tested 
Predictors of testing 
[27] Abtew, (2015) 2014 North-West 
Ethiopia. 1 
hospital, 1 health 
centre (developing 
urban). 
Cross-sectional 
(386) 
15 – 49-year-old 
pregnant women 
attending the 
health facilities. 
81% Not reported  Living in rural areas 
 Berta ethnic group 
 Merchants, students and 
employed 
 Favorable attitude 
towards PITC 
 No HIV/AIDs 
stigmatization 
[28] Akinleye, (2017) 2014 Nigeria. 13 Local 
Government Areas 
in Benue State 
(high HIV 
prevalence). 
Cross-sectional 
(50,271) 
Pregnant women 
residing in Benue 
State receiving 
any MNCH 
service during 
the week. 
100%* (in MNCH 
week) 
2%  Gestational age (3rd 
trimester) 
[29] Alemu, (2017) 2012 - 2013 Northern Ethiopia. 
4 PHC centers. 
Low income 
settings. 
Cross-sectional 
(416) 
Pregnant women 
attending their 
first ANC visit. 
67% Not reported  Younger age (16 -24 
years) 
 Higher education 
 From urban areas 
 Higher monthly 
expenditure 
 Nulliparous 
 Knowledge of MTCT & 
PMTCT 
 Favorable attitude 
towards HIV/ AIDS 
[30] Chizoba, (2017) 2015 Ebonyi Nigeria. 20 
PHCs in 
intervention and 
control groups. 
Quasi-
experimental 
(not specified) 
Pregnant women 
attending PHC 
centers in 
Ebonyi. 
Not reported Not reported Not reported 
[31] Dako-Gyeke, 
(2016) 
2011 - 2013 Ghana 
(nationwide). 
Retrospective 
programme data 
review 
(2,215,090) 
Pregnant women 
registered at 
antenatal clinics 
around the 
country. 
Overall: 78% 
2011: 83% 
2012: 76% 
2013: 75% 
≤ 3%† Region and 
year dependent 
Not reported 
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In-text 
citation 
Author, (year)  Study period Setting Design (sample 
size) 
Population Testing 
proportion 
(antenatal) 
HIV prevalence 
among women 
tested 
Predictors of testing 
[26] Dzangare, (2016) 2014 Zimbabwe. 34 
MCH facilities in 
rural Chikomba 
and Gutu districts. 
Retrospective 
cohort (2598) 
Women who 
registered/ 
presented: in 
ANC, labour, or 
MCH while 
breastfeeding. 
81% 7%  Attending hospitals vs 
health centers 
 Low parity 
 1st ANC visit ≤ 28 weeks 
 “booking” 
[32] Gamell, (2017) 2014 – 2015 South-West 
Tanzania (rural). 
Saint Francis 
Referral Hospital 
(SFRH). 
Prospective 
cohort (1579) 
Pregnant women 
attending the 
Ifakara One Stop 
Clinic at SFRH. 
94% 3% Not reported 
[33] Gazimbi, (2018) 2005/6 & 
2010/11 
Zimbabwe 
(nationwide). 
Secondary 
analysis on DHS. 
Cross-sectional  
(8471) 
Women who had 
given birth within 
5 years preceding 
the survey. 
56% (2010/11) Not reported  Year of pregnancy 
 Age (younger) 
 Marital status 
 Higher education 
 Low Parity 
 Higher Wealth 
 Media 
 Access to health care 
 Lack of HIV/AIDs stigma 
 Community awareness 
 Community stigma 
[25] Gunn, (2016) Congo, 
Mozambique & 
Uganda: 2011 – 
2012 
Nigeria: 2013 
Nationwide: 
Congo, 
Mozambique, 
Uganda & 
Nigeria. 
Secondary 
analysis on DHS. 
Cross-sectional  
(not specified) 
Women who 
received ANC 
during their last 
pregnancy – 
within 5 years 
preceding the 
survey. 
Overall: 61% 
Uganda: 82% 
Mozambique: 
69% 
Nigeria: 54% 
Congo: 46%. 
Not reported Individual level: 
 Age (younger) 
 Higher education 
 Urban residence 
 Higher wealth index 
 No HIV stigma 
 HIV knowledge 
Health system level: 
 Facility access 
 Services from skilled 
attendant 
42 
 
In-text 
citation 
Author, (year)  Study period Setting Design (sample 
size) 
Population Testing 
proportion 
(antenatal) 
HIV prevalence 
among women 
tested 
Predictors of testing 
[35] Kim, (2015) 2009 – 2011; 
2011 – 2013 
Lilongwe Malawi. 
Urban health 
centers. 
Pre/post B+ 
quasi-
experimental 
study 
(13,926 (pre); 
14,532 (post)) 
Pregnant women 
enrolled in the 
Tingathe 
programme 
antenatally. 
Pre-Option B+:  
99% 
 
During Option B+: 
 88% 
Pre-Option B+:  
10% 
 
During Option B+: 
7% 
Not reported 
[34] Ndedge, (2016) 2008 – 2012 Western Kenya. Retrospective 
cohort study on 
HBCT 
(7396) 
Women aged 13-
50 years. 
97% for HBCT 
(among pregnant 
women) 
Overall: 7% 
 
ANC attenders: 5% 
 
Non-ANC 
attenders: 9% 
 Having not attended 
ANC 
 Higher education 
 Younger age 
 Unmarried 
 Higher income 
[24] Semali, (2014) 2011 - 2012 Tanzania 
(nationwide). 
Secondary 
analysis on 
THMIS. Cross-
sectional  
(3555) 
Women who had 
given birth 2 
years preceding 
the survey. 
76% Not reported  Age (35+) 
 Higher wealth 
 Higher education 
 Info on testing during 
ANC 
[23] Tenthani, (2015) 2010 – 2014 Southern & 
Central Malawi. 
Sites with EMR 
ART system in 
2011. 
Retrospective 
cohort study 
(individual-level 
data: 100,515) 
 
(aggregated data:  
194,345) 
Pregnant women 
who attended 
ANC. 
Overall: 85% 
Pre-Option B+:  
82% 
During Option B+: 
86% 
Not reported  Being older (20+ years) 
 Registering in 2010 
 >1 antenatal visit 
* Actual proportion is 99.96%, but has been rounded up to 100%. 
†Denominator is all women receiving ANC. 
ANC: antenatal care; MCH: maternal and child health services; PHC: primary health care; PITC: provider-initiated testing and counselling; MTCT: mother-to-child transmission; PMTCT: 
prevention of mother-to-child transmission; MNCH: maternal, newborn and child health; DHS: demographic health survey; HBCT: home-based counselling and testing; THMIS: Tanzania 
HIV/AIDS and Malaria Indicator Survey; EMR: electronic medical records 
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Table 2. Summary of studies including repeat/late pregnancy HIV testing as an outcome of interest. 
In-text 
citation 
Author, (year) Study period Setting Design 
(sample size) 
Population Testing proportion 
(antenatal/repeat) 
HIV prevalence & 
incidence among 
women tested 
Predictors of testing 
[41] Bello, (2011) 2005 – 2006 South-West 
Nigeria. Labour 
ward, University 
College 
Hospital. 
Cross-sectional 
study (104) 
Unregistered 
pregnant 
women 
presenting for 
delivery. 
At labour: 87% of 
unregistered 
individuals. 
Prevalence at 
labour: 7% 
 Being less educated 
[45] Ekouevi, (2012) 2010 Togo. Teaching 
hospital, 
obstetrics unit. 
Cross-sectional 
study (508) 
Pregnant 
women 
admitted to 
the hospital for 
delivery. 
Antenatal: 71%  
 
At labour: 92% of 
which 70% were 
retests. 
Prevalence at 
labour: 9%  
 Not reported 
[47] Heemelaar, 
(2015) 
2012 Zambia. SFH, a 
rural district 
hospital in 
Katete. 
Prospective, 
implementation 
cross-sectional 
study 
(322)  
Women 
delivering at 
the SFH. 
Antenatal: 94%  
 
Repeat 
(antenatally/delivery): 
25%  
Prevalence at 
labour: 8%† 
 Not reported 
[42]
 
Kieffer, (2011) 2008 - 2009 Swaziland. 4 
hospitals (2 
urban, 2 rural), 
2 rural health 
centers. 
Quasi-
experimental 
study (2444) 
Pregnant 
women 
presenting for 
delivery. 
Antenatal:  91% 
 
Repeat (delivery): 
Intervention site: 45% 
Control site: 14% 
 
At labour (1
st
 test): 
Intervention site: 96% 
Control site: 65% 
Prevalence among 
women 
“unbooked” at 
delivery: 
Intervention site: 
35% 
Control site: 45% 
 
Incidence: 4% 
 Not reported 
[49] Mtaja, (2014) Not reported Zambia. 
Postnatal 
clinic at Chilenje 
Health Centre in 
Lusaka. 
Cross-sectional 
study 
(404) 
Postnatal 
mothers 
attending their 
6
th
 week visit. 
Antenatal: 100%  
 
Repeat (antenatally): 
36%  
Not reported  Booking in 1st 
trimester 
 5 or more ANC visits 
 Awareness of repeat 
testing 
[48] Onakewhor, 
(2013) 
2009  Nigeria. 
Hospital 
obstetrics unit. 
Prospective cohort 
study (415) 
Antenatal 
women testing 
negative at 
“booking” (≥ 
12 weeks 
before labour). 
At labour: 96% 
 
Incidence at 
labour: 0.25%  
 Maternal age ≥25 
years 
 Secondary & post-
secondary education 
 Parity ≥1 
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In-text 
citation 
Author, (year) Study period Setting Design 
(sample size) 
Population Testing proportion 
(antenatal/repeat) 
HIV prevalence & 
incidence among 
women tested 
Predictors of testing 
[46] Rogers, (2017) 
 
 
2011 - 2014 Kenya. 
Government 
hospital, 
rural 
southwestern 
area with 
highest HIV 
prevalence. 
Longitudinal 
cohort study 
(2145; 1375 
eligible for retest) 
Women 
attending the 
hospital 
antenatal clinic 
from 2011 to 
2014. 
First ANC visit: 78%  
 
1
st
 test + 12 weeks: 
27% of those eligible 
Prevalence at 
labour: 26%† 
 
Incidence: 2%  
 Marital status. 
 Year of pregnancy. 
†Denominator is all study participants. 
ANC: antenatal care; SFH: Saint Francis Hospital
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1. Abstract 
 
Introduction: The virtual elimination of mother-to-child transmission (MTCT) of HIV cannot 
be achieved without complete maternal HIV testing. In 2014, the Western Cape Province 
(South Africa) prevention of mother-to-child transmission (PMTCT) guidelines  
recommended a repeat maternal HIV test between 32 - 34 weeks gestation and at delivery 
in addition to testing at “booking”, the first antenatal visit (<20 weeks gestation). There is 
limited literature on the uptake of and adherence to maternal HIV testing programmes in 
sub-Saharan Africa. 
Methods: Between 2013 and 2016 we established an electronic PMTCT register (e-register) 
that consolidated routine data from a primary healthcare facility and its secondary and 
tertiary referral sites in Cape Town, South Africa. This provided a single longitudinal record, 
from antenatal care to delivery, for each pregnant woman. Utilizing these data, we 
conducted a retrospective sub-analysis investigating the completeness (until delivery) of 
maternal HIV testing according to the PMTCT maternal HIV testing guidelines in Cape Town, 
and predictors of complete testing, from 1 July 2014 – 31 December 2016. 
Results: Among 8558 enrolled women, 7213 were not diagnosed HIV-positive prior to their 
first visit and thus eligible for HIV testing in pregnancy. Among these women, 91% received 
≥1 HIV test. Among 85% who “booked” (i.e. presented for antenatal care) >5 days before 
delivery, testing completeness at “booking” was 98%. Among women eligible to receive 
tests at all 3 recommended timepoints, only 10% were HIV tested according to the 
guidelines. Delivery HIV testing completion among all women not yet diagnosed HIV-
positive was 23%. HIV prevalence at delivery was 21% and HIV incidence between “booking” 
and delivery in those with ≥2 HIV tests was 0.2%. Women who enrolled after 2014 were less 
likely to miss ≥1 of the three recommended tests (aOR: 0.70; CI: 0.55 – 0.90) and not test at 
delivery (aOR: 0.63; CI: 0.55 – 0.71) compared to those that enrolled in 2014.  
Conclusion: Maternal HIV testing within the PMTCT programme in Cape Town has matured 
post 2014 with improved implementation over time; however, there are still major 
implementation gaps, particularly at delivery.  
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2. Introduction 
 
The implementation of policies recommending immediate lifelong triple antiretroviral 
therapy (ART) initiation for all HIV-positive pregnant women (Option B+) has been shown to 
be effective in reducing mother-to-child transmission (MTCT) of HIV worldwide [1,2]. 
Women’s access to these and other HIV-related services in the prevention of MTCT (PMTCT) 
continuum relies on complete universal antenatal care (ANC) HIV testing, which is essential 
for the virtual elimination of MTCT of HIV [3,4]. It is estimated that failure to detect 
maternal HIV infection during ANC is responsible for up to 54% of MTCT in resource-limited 
settings [5]. 
The World Health Organization (WHO) recommends that provider-initiated HIV testing and 
counselling, forming part of ANC services, be offered to pregnant women at their first ANC 
visit recommended at ≤ 12 weeks gestation [6,7]. Not only will this enable the timely 
diagnoses of undiagnosed pregnant women living with HIV, it will also provide HIV-negative 
women with guidance counselling and services to assist with the prevention of HIV 
acquisition and the opportunity to retest later during the pregnancy [8]. In 2010, WHO 
recommended that women in areas with generalized HIV epidemics are repeat tested for 
HIV in either the third trimester, at delivery, or directly thereafter [9]. In 2014, in the 
Western Cape (WC) Province, South Africa (SA), the Western Cape Prevention of Mother-to-
Child Transmission of HIV (PMTCT) Clinical Guidelines recommended a repeat test between 
32 - 34 weeks gestation and again at delivery, subsequent to testing at first ANC visit 
(referred to as the “booking” visit) recommended at < 20 weeks gestation [10]. Retesting is 
important as women are more likely to acquire HIV infection during pregnancy, and, if 
acutely infected, MTCT risk is increased [11–15]. In addition, the rapid antibody tests may 
not accurately diagnose HIV during the window period (up to 3 months post acquisition) 
[13]. In settings such as SA where >80% of deliveries occur in facilities [16], HIV testing at 
delivery provides a particular opportunity to test women with an unknown HIV status who 
do not attend ANC – referred to as “unbooked” [17,18].  
Across sub-Saharan Africa (SSA) antenatal HIV testing proportions range from 46% - 99%, 
but are mostly below the minimum 90% required to enable 90% of HIV-positive pregnant 
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women access to ART [4,19–22]. However, most of these studies were conducted before 
2015 with very few reporting on post Option B+ policy implementation testing completion. 
Furthermore, these studies often use self-report to determine HIV testing completion which 
could skew results due to reporting bias. In order to better understand the current (i.e. post-
Option B+) implementation and uptake of antenatal HIV testing in SSA studies utilizing 
recent routine data from ANC services is required. Additionally, since repeat HIV testing is 
implemented sequentially throughout pregnancy, potentially involving multiple service 
providers, longitudinal maternal data is needed to accurately estimate repeat testing 
coverage. However very few studies have collected such data and thus reports on coverage 
of repeat/delivery HIV testing in SSA are lacking [23].  
Utilizing prospectively collected, individual-level, longitudinal patient data from a primary 
health care facility and its referral sites (secondary and tertiary) we aimed to investigate the 
implementation of and adherence to “booking” and repeat maternal HIV testing PMTCT 
guidelines (up until delivery) in Cape Town, SA. We assessed the coverage and timing of 
initial HIV testing during pregnancy, repeat HIV testing in the recommended testing 
windows (including delivery), HIV prevalence and incidence among those tested, and the 
predictors of missed testing opportunities.  
 
3. Methods 
 
3.1 Study design 
 
This study was a retrospective sub-analysis carried out on antenatal maternal HIV testing 
data that were prospectively collected for the Closing the Gaps (CTG) study which has been 
described previously [24]. Briefly, the CTG study established an integrated electronic PMTCT 
register (e-register) that consolidated routine data from a primary care antenatal and 
delivery facility, Mitchells Plain Midwife Obstetric Unit (MPMOU), and its referral sites: 
Mitchell’s Plain District Hospital (MPDH), Mowbray Maternity Hospital (MMH) and Groote 
Schuur Hospital (GSH), within the urban Klipfontein sub-district of the WC, SA.   
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3.2 Study setting 
 
At the time of the study MPMOU, a primary care facility that served approximately 1.2 
million people, provided ANC and midwife-administered uncomplicated vaginal delivery 
services [25]. The 2015 WC antenatal HIV prevalence was reported to be 19% [26]. 
High risk pregnancies or those requiring advanced care were referred from MPMOU to a 
secondary or tertiary care facility during the antenatal or peri-partum period. MPDH and 
MMH (secondary level) are equipped with operating theatres and neonatal intensive care 
unit (ICU) facilities respectively while GSH (tertiary level) has both adult and neonatal ICU 
facilities. 
 
3.3 Study participants 
 
In the CTG study pregnant women, irrespective of HIV status, were automatically enrolled at 
their first ANC visit (“booking”) at MPMOU, or alternatively upon presentation for delivery if 
they had not received ANC. Point-of-care rapid HIV tests (i.e. antibody assays for HIV-1 and 
HIV-2), were performed by community care workers as part of routine ANC services and by 
nurses in the labour ward of MPMOU and the labour/post-natal ward of the hospitals. The 
HIV status of women who presented as “known” HIV-positive at their first visit was 
confirmed from clinical records or HIV retesting if they were not on ART. 
 In July 2014 the WC PMTCT guidelines were updated with respect to repeat HIV testing 
[10]. We therefore included women enrolling in the CTG study from 1 July 2014 onwards i.e. 
who were included in this policy period. We included data from the CTG e-register for all 
women who delivered at MPMOU or one of its referral sites between 1 July 2014 – 31 
December 2016 with a live or still birth pregnancy outcome. We excluded data from women 
who a) presented for delivery having “booked” at a community basic antenatal clinic (banc) 
since we did not have access to complete longitudinal HIV testing data for these individuals 
or b) for whom no pregnancy outcome could be found as we could not exclude pregnancy 
loss in which case PMTCT testing guidelines would no longer be applicable. Furthermore, in 
the absence of a documented pregnancy outcome and visit data it is unknown whether 
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participants transferred out to other facilities and at what point during pregnancy they 
would have done so. Retaining these individuals in the dataset could potentially have biased 
study results to underestimate repeat testing completion. 
 
3.4 Procedures and measurements 
 
A single longitudinal record, including HIV testing history from first antenatal visit (if 
attended) through to delivery, for each mother was extracted from the CTG e-register. We 
categorized women as having “booked” for delivery if they presented to a health facility >5 
days before delivery. We considered women to have tested: at “booking” if they presented 
before delivery and tested at their first visit; within the first time period (20 weeks 
gestation) if an HIV test occurred before 22 weeks gestation; during the third trimester if 
they had an HIV test between 28 weeks gestation and 5 days before delivery; and at delivery 
if they had an HIV test within ±5 days of delivery. We deemed women eligible for an initial 
test if on their first visit, whether antenatally or at delivery, they did not have a known HIV-
positive status; and eligible for retesting if they had not had a prior positive antenatal HIV 
test. Tests were considered to be retests if women underwent an HIV test within a 
recommended time period following a prior HIV-negative test.  
We calculated testing completion at “booking” among all women who “booked” before 
delivery (Figure 1). Testing completion during each recommended window was calculated 
only among women eligible to be tested in that window as follows: first window – “booked” 
with an unknown/negative HIV status before 22 weeks gestation; third trimester - “booked”  
before/during the third trimester, not previously diagnosed HIV-positive and not delivered 
before 28 weeks plus 5 days gestation; delivery - all eligible irrespective of gestational age at 
delivery, “booking” status or testing history, if not previously diagnosed HIV-positive. We 
reported testing outcomes as proportions as the study was based on routine data and we 
did not have outcome time for all women. 
We coded women as having “missed testing opportunities” if they a) did not test at all or b) 
failed to test during ≥1 of the recommended time periods. Individuals diagnosed HIV-
positive during the study period were coded as “diagnosed at enrolment” if they tested HIV-
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positive at their initial “booking” test, or alternatively as “seroconverts” if they tested HIV-
positive after a previous negative antenatal HIV test. We coded women as having an 
“uncertain HIV status at delivery” if they tested at least once during ANC but did not test 
within 3 months before delivery or at delivery, and having an “unknown HIV status at 
delivery” if they never tested during the current pregnancy. 
For women with two pregnancies within the study period, we included the pregnancy for 
which most data were available.  Women who delivered <37 weeks gestation were coded as 
having a premature delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Women that delivered within the first five days of the subsequent period and therefore would not be eligible 
for testing in that period 
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Figure 1. Flow chart illustrating the number of women eligible to be HIV tested within each 
testing window. Only women for whom gestational age was available were included (n=6860). 
58 
 
3.5 Data analysis 
 
Data analysis was carried-out using Stata version 13.0 (Stata Corporation, College Station, 
Texas, USA). We summarized normally and non-normally distributed continuous variables 
using means and confidence intervals (CI) or medians and interquartile-ranges (IQR) 
respectively. Categorical variables were described and compared using proportions and 
frequency tables or graphical displays. Differences were assessed using the two-sample t-
test (normal distribution) or the Wilcoxon rank-sum test (non-normal distribution) for 
numerical data and the χ2 or Fishers Exact test for categorical data. We used logistic 
regression to assess predictors of not testing: at all, at “booking”, at delivery and not 
receiving the 3 recommended tests. Multivariable models included several variables (age at 
enrolment, gravidity, & year of enrolment) a priori as being possible risk factors for the 
outcome of interest. Other variables were included in the models by sequentially adding 
them based on univariable analysis significance. Those that were either significantly 
associated with the outcome of interest after adjustment for other variables (p<0.05) or 
that altered the odds ratios (ORs) for other variables in the model by ≥10% were retained.  
 
3.6 Missing data 
 
Data were missing for gestational age, gravidity, delivery facility and premature delivery 
variables. We retained individuals in the dataset for whom data were missing. When 
assessing testing completion we only included individuals for whom gestational age data 
were available. Individuals with missing data were excluded for logistic regression using 
listwise deletion. 
 
3.7 Ethics 
 
The University of Cape Town Human Research Ethics Committee and the Provincial 
Government of the Western Cape Department of Health Research approved the study. 
59 
 
The CTG study was granted a waiver of informed consent for the e-register as all data had 
already been collected routinely by health services. No participant recruitment was required 
and data was deidentified prior to analysis. 
 
4. Results 
 
4.1 Participant characteristics 
 
Between July 2014 and December 2016, 8558 women delivered at MPMOU or one of its 
referral sites with a live or still birth pregnancy outcome (Table 1). Within the study period, 
153 women had two pregnancies of which only one pregnancy was analysed.  
HIV-negative/uncertain vs. HIV-positive women were more likely to attend ANC (%: 93 vs. 
81; p<0.001) and presented earlier for their first ANC visit (median [IQR] gestation: 21 [15-
29] vs. 24 [18-35] weeks; p<0.001) (Table 1). At delivery, HIV status was confirmed in 75% of 
the cohort of whom 21% were positive. Among HIV-positive women, 95% were known 
positive (confirmed from clinical records or retested if not on ART) at first ANC visit, 4% 
were newly diagnosed at their first test in the current pregnancy and 0.7% seroconverted 
during pregnancy after initially testing HIV-negative. Of the women who tested HIV-negative 
antenatally, 22% had an uncertain HIV status at delivery (not tested within 3 months of 
delivery/at delivery). Among all women, 8% did not test during pregnancy/delivery at all. In 
total, 31% of all women who had not been diagnosed HIV-positive before delivery had an 
unconfirmed HIV status (i.e. either uncertain or not tested at all during ANC) after delivery.  
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Table 1. Characteristics of 8558 participants stratified by HIV status post-delivery. Characteristics at first 
visit (baseline) and delivery are reported.†  
Variable HIV-negative/ 
uncertain‡  
HIV-positive 
 
P-value § Never 
tested 
 n = 6557 (77%) n = 1345 (16%)  n = 656 (8%) 
Baseline characteristics 
Age (years): n (%)     
13 - <16 76 (1) 3 (0.2) 
<0.001 
6 (1) 
16 - <21 1074 (16) 75 (6) 111 (17) 
21 - <31 3789 (58) 771 (57) 415 (63) 
31 - <41 1506 (23) 481 (36) 116 (18) 
41 - <47 103 (2) 15 (1) 8 (1) 
Median (IQR) 26 (22-31) 29 (25-33) <0.001 26 (22-30) 
Gravidity: n (%)      
1 2019 (31) 236 (17) 
<0.001 
171 (26) 
2 1922 (29) 475 (35) 188 (29) 
3 1312 (20) 373 (28) 121 (18) 
≥4 1197 (18) 226 (17) 167 (26) 
Missing 107 (2) 35 (3) 9 (1) 
Enrolment year: n (%)     
2014 2365 (36) 497 (37) 
0.54 
313 (48) 
2015/2016 4192 (64) 848 (63) 343 (52) 
Antenatal care: n (%)     
Yes 6080 (93) 1096 (81) 
<0.001 
63 (10) 
No 477 (7) 249 (19) 593 (90) 
Gestational age at first visit (weeks): n (%) 
  
  
≤12 926 (14) 97 (7) 
<0.001 
4 (0.6) 
>12 - 20 1930 (29) 331 (25) 16 (2) 
>20 - 28 1748 (27) 362 (27) 17 (3) 
>28 - 36 992 (15)  202 (15) 43 (7) 
≥37 628 (10) 281 (21) 546 (83) 
Missing 333 (5) 72 (5) 30 (5) 
Median (IQR) 21 (15-29) 24 (18-35) <0.001 40 (40–40) 
Delivery characteristics 
Delivery facility: n (%)     
MPMOU 2648 (40) 551 (41) 
0.09 
422 (64) 
MPDH 2264 (35) 485 (36) 160 (24) 
MMH 1164 (18) 231 (17) 63 (10) 
GSH 460 (7) 78 (6) 11 (2) 
Missing 21 (0.3) 0 (0) 0 (0) 
Premature deliveries: n (%)     
Yes 607 (9) 110 (8) 
0.46 
48 (7) 
No 5617 (86) 1166 (87) 7361 (88) 
Missing 333 (5) 69 (5) 30 (5) 
Birth outcome: n (%)     
Alive  6468 (99) 1320 (98) 
0.17 
643 (98) 
Stillborn 89 (1) 25 (2) 13 (2) 
HIV status at delivery: n (%)     
Known HIV-positive before enrolment - 1277 (95) 
- 
- 
Diagnosed HIV-positive at first visit - 59 (4) - 
Seroconverts - 9 (0.7) - 
HIV-negative 5092 (78) - - 
Previously HIV-negative‡ 1465 (22) - - 
Not tested - - 656 (100) 
†Values are rounded to the nearest whole number and proportions do not always add up to 100%/variable. 
‡ Individuals that were last tested during antenatal care ≥ 3 months before delivery and therefore have an uncertain HIV 
status at delivery. 
§ P-values are reporting the significance of the difference between HIV-negative/uncertain & HIV-positive. 
n: number of participants; IQR: Interquartile range; MPMOU: Mitchells Plain Midwife Obstetric Unit; MMH: Mowbray 
Maternity Hospital; MPDH: Mitchells Plain District Hospital; GSH: Groote Schuur Hospital 
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4.2 HIV testing characteristics 
 
Of all women eligible for testing (n=7281), i.e. not been diagnosed HIV-positive before the 
current pregnancy, 91% received ≥1 HIV test. 
Among 7222 women eligible for >1 HIV test i.e. having not been diagnosed HIV-positive at 
booking, 44% had 2 tests throughout pregnancy (including delivery) and 9% had ≥3 tests 
(Figure 2). When stratifying the number of HIV tests received by “booking” status, among 
1070 “unbooked” women, 55% did not test at all compared to 1% of 6152 “booked” women 
(p<0.001). Fifty-four percent of HIV-negative/uncertain women had their first HIV test by 22 
weeks compared to 40% of newly diagnosed HIV-positive individuals (p=0.02) (Table 2).  
 
Table 2. Gestational age at first HIV test, stratified by HIV status at delivery, for participants that were 
HIV-negative/unknown at enrolment (n =6291†). 
Gestational age at first 
test (weeks): n (%) 
HIV-negative/uncertain 
n = 6224  
HIV-positive  
n = 67  
p-value Total 
≤12 917 (15) 4 (6) 
0.05 
921 (15) 
>12 - 22 2414 (39) 23 (34) 2437 (39) 
>22 - 28 1235 (20) 22 (33) 1257 (20) 
>28 - 36 1002 (16) 10 (15) 1012 (16) 
≥37 656 (11) 8 (12) 664 (11) 
Median (IQR) 21 (15-29) 23 (16-29) 0.09 21 (15–29) 
†Only individuals that tested ≥1 and for whom gestational age was available were included. 
Figure 2. Number of HIV tests received, stratified by “booking” status, among those that were not 
known HIV-positive or diagnosed HIV-positive at their first test (n=7222). 
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4.3 HIV testing completeness by gestational age and HIV incidence 
 
Among all women HIV-negative/unknown at first visit and for whom gestational age data 
were available (n=6917), 85% “booked” at MPMOU >5 days before delivery with 98% HIV 
testing completeness at “booking” (Table 3). Among 49% of HIV-negative/unknown women 
who “booked” at ≤22 weeks gestation, 0.7% (23/3358) were newly diagnosed HIV-positive. 
Among the 4504 (77%) of women who had previously tested HIV-negative during their 
current pregnancy, 60% were retested during the 3rd trimester of whom 0.2% (6/2972) 
seroconverted. 
Among “unbooked” women (i.e. did not attend any ANC) (n= 1023), only 45% were tested 
for HIV at delivery, of whom 1.5% (7/479) were newly diagnosed HIV-positive. Out of those 
women who had tested earlier in pregnancy, 19% re-tested at delivery, of whom 3 women 
(0.3%) had seroconverted. The highest delivery HIV testing completion was at the two 
secondary level facilities (MPDH: 32% and MMH: 21%) (Figure S2). Among women who 
“booked” in the first window, had gestational age at delivery >28 weeks and 5 days, and 
were not diagnosed HIV-positive before delivery (hence eligible to have all three 
recommended tests) (n =3356), 10% received HIV tests in all three windows (Table 4). Out of 
the 5% of women who were diagnosed HIV-positive during pregnancy/delivery, 64% were 
diagnosed at their first test before the third trimester while 9% were seroconversions within 
the third trimester (Figure S3). Amongst the 61% (Figure 2) of “booked” women who had >1 
HIV test, 0.2% seroconverted. 
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Table 3. HIV testing during pregnancy for women for whom gestational age data were available (n=6917). 
 Total 
women† 
All women eligible 
for testing‡ 
Women untested in current pregnancy Women previously tested in current 
pregnancy 
  New visits/bookings Previously booked   
Testing point/window n n (%) % tested n (%) % tested n (%) % tested % positive at 
first test∆ 
n (%) % tested % positive at 
repeat test¥ 
Booking§ 6917 5894 (85) 98 5894 (100) 98 - - 0.9 - - - 
≤22 weeks 6917 3408 (49) 99 3408 (100) 99 - - 0.7 -  -  -  
>22 - < 28 weeks¶ 6893 4618 (67) 28 1234 (27) 99 50 (1) 2 1.6 3334 (72) 2 0 
28 weeks – <delivery 6828 5823 (85) 68 1252 (22) 97 67 (1) 33 0.7 4504 (77) 60 0.2 
Delivery 6860 6860 (100) 23 1023 (15) 45 82 (1) 28 1.5 5755 (84) 19 0.3 
n: number of participants 
†Total women at each testing window excludes those that were diagnosed HIV-positive during the previous window as well as those that delivered prematurely in the previous window or in 
the first 5 days of the current window. Women eligible at delivery and booking are regardless of time point. 
‡ Eligibility is based on booking status. Women are eligible to test if they booked within the current or previous testing window. At delivery women are eligible regardless of booking status. 
§ Booking is reported as a separate testing “window” in addition to testing completeness from longitudinal analysis. Unbooked women excluded. 
¶ The >22 - <28 weeks testing window, although not a recommended testing window, was included in this analysis to incorporate individuals who may have tested outside the first 
recommended window but would still be eligible for retesting in the later windows. 
∆ % positivity was calculated as a proportion of those that tested for the first time within that window. 
¥ % positivity was calculated as a proportion of those that were receiving a repeat test in that window. The denominator included individuals who booked and had >1 test within the window. 
 
Table 4. Longitudinal HIV testing completion proportions among women with known gestational age who were eligible to receive all three recommended tests. 
Testing window Women eligible: n† Women tested: n (%) 
≤22 weeks 3408 3358 (99) 
28 weeks – <delivery 3310 2062 (62) 
Delivery 2059 347 (17) 
All 3 tests‡ 3356 347 (10) 
†Eligibility is based on women having strictly tested in previous recommended windows. At the first time point only those who had booked and for whom gestational age data were available 
were eligible. This number also excludes those that delivered or were diagnosed prior to a specific window. Only those that delivered after the start of the third trimester were considered to 
be eligible at delivery. 
‡All 3 tests includes women that booked in the first window, weren’t diagnosed HIV-positive before delivery and delivered >5 days after the start of the third trimester.
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4.4 Predictors of maternal HIV testing missed opportunities 
 
Amongst all eligible women, 9% had no HIV tests during pregnancy/delivery (Figure 2). In 
multivariable analysis late gestational age at “booking” (aOR: 1.10; CI: 1.07 – 1.13, per 
additional week gestation) and delivering at MPDH (aOR: 1.50; CI: 1.11 – 2.04); or MMH 
(aOR: 1.98; CI: 1.32 – 2.98); vs. MPMOU were associated with having no HIV test at all (Table 
5). “Booking” (aOR: 0.02; CI: 0.01 – 0.04) vs. never “booking” and enrollment in 2015/2016 
(aOR: 0.38; CI: 0.30 – 0.49) vs. 2014 were associated with being less likely to miss all testing 
opportunities.  
Among eligible women, 10% received all three of the recommended HIV tests (Table 4). The 
following factors were associated with being less likely to miss ≥1 of the 3 recommended 
tests: full-term pregnancy (aOR: 0.60; CI: 0.37 – 0.95) vs. premature delivery; enrollment in 
2015/2016 (aOR: 0.70; CI: 0.55 – 0.90) vs. 2014; and delivering at MPDH (aOR: 0.09; CI: 0.06 
– 0.14); or MMH (aOR: 0.20; CI: 0.12 – 0.32); vs. MPMOU (Table 5).  
Among women eligible for HIV testing at delivery (i.e. all women of negative/unknown HIV 
status), 23% tested (Table 3). In multivariable analysis “booking” (aOR: 3.96; CI: 2.90 – 5.49) 
vs. never “booking” was associated with not testing at delivery (Table 5). The following 
factors were associated with being less likely to miss the delivery test: enrollment in 
2015/2016 (aOR: 0.63; CI: 0.55 – 0.71) vs. 2014; having received no ANC testing (aOR: 0.72; 
CI: 0.55 – 0.94), or having only tested ≤22 weeks (aOR: 0.73; CI: 0.61 – 0.88) vs. having 
tested in recommended windows one and two; and and delivering at MPDH (aOR: 0.25; CI: 
0.21 – 0.29); or MMH (aOR: 0.48; CI: 0.39 – 0.58); vs. MPMOU.  Among “unbooked” women, 
those that enrolled in 2015/2016 vs. 2014 were less likely to miss the delivery HIV testing 
opportunity (aOR: 0.40; CI: 0.30 – 0.53) (Table S1).  
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Table 5. Univariable and multivariable factors associated with failure to A. test both antenatally and at delivery, B. receive the three recommended tests, C. test 
at booking and D. test at delivery. 
 A. No maternal HIV testing            
n = 6886  
B. Not receiving three 
recommended tests†         
n = 3344 
C. Not testing at booking             
n = 5867 
D. No testing at delivery               
n = 6790 
Variable OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) 
Age at first visit (years) 0.98 (0.97; 0.99) 0.98 (0.96; 1.01) 1.01 (0.99; 1.03) 1.00 (0.97; 1.02) 1.00 (0.97; 1.03) 0.99 (0.96; 1.03) 1.00 (0.99; 1.01) 1.00 (0.99; 1.02) 
Booked: No Ref Ref * * * * Ref Ref 
Yes 0.01 (0.006; 0.01) 0.02 (0.01; 0.04) * * * * 3.46 (3.01; 3.97) 3.96 (2.90; 5.49) 
Gestational age at first visit 
(weeks) 
1.35 (1.32; 1.39) 1.10 (1.07; 1.13) * * 1.05 (1.03; 1.07) 1.04 (1.02; 1.07) 0.97 (0.96; 0.97) 0.99 (0.98; 1.01) 
Gravidity: 1 Ref Ref Ref Ref Ref Ref Ref Ref 
2 1.15 (0.93; 1.43) 0.97 (0.69; 1.38) 1.32 (1.01; 1.73) 1.17 (0.87; 1.58) 1.12 (0.71; 1.77) 1.14 (0.70; 1.86) 1.20 (1.03; 1.39) 1.12 (0.94; 1.32) 
3 1.09 (0.85; 1.38) 0.73 (0.49; 1.10) 1.40 (1.02; 1.94) 1.18 (0.81; 1.72) 0.78 (0.44; 1.38) 0.80 (0.42; 1.53) 1.09 (0.92; 1.28) 0.97 (0.79; 1.19) 
≥4 1.65 (1.32; 2.07) 0.65 (0.42; 1.02) 1.30 (0.92; 1.84)  1.13 (0.73; 1.76) 1.60 (0.98; 2.60) 1.56 (0.81; 3.01) 0.77 (0.66; 0.90) 0.77 (0.61; 0.96) 
Premature delivery: Yes Ref * Ref Ref * * Ref * 
No 1.29 (0.95; 1.76) * 0.61 (0.39; 0.94) 0.60 (0.37; 0.95) * * 1.18 (0.98; 1.43) * 
Mode of delivery: Vaginal Ref * Ref Ref * * Ref * 
Assisted 0.48 (0.12; 2.00) * 0.40 (0.13; 1.20) * * * 0.64 (0.31; 1.35) * 
BBA 3.88 (2.72; 5.52) * * * * * 0.34 (0.24; 0.47) * 
Caesarean section 0.43 (0.34; 0.55) * 0.52 (0.41; 0.65) * * * 0.79 (0.70; 0.90) * 
Outcome: Alive Ref * Ref * * * Ref * 
Still Born 1.47 (0.82; 2.64) * 2.08 (0.28; 15.65) * * * 0.58 (0.36; 0.96) * 
Year of enrolment: 2014 Ref Ref Ref Ref Ref Ref Ref Ref 
2015/2016 0.63 (0.54; 0.74) 0.38 (0.30; 0.49) 0.76 (0.60; 0.96) 0.70 (0.55; 0.90) 0.48 (0.34; 0.69) 0.51 (0.35; 0.72) 0.70 (0.62; 0.79) 0.63 (0.55; 0.71) 
Delivery facility: MPMOU Ref Ref Ref Ref * * Ref Ref 
MPDH 0.44 (0.37; 0.54) 1.50 (1.11; 2.04) 0.10 (0.06; 0.14) 0.09 (0.06; 0.14) * * 0.41 (0.36; 0.47) 0.25 (0.21; 0.29) 
MMH 0.34 (0.26; 0.44) 1.98 (1.32; 2.98) 0.23 (0.14; 0.37) 0.20 (0.12; 0.32) * * 0.74 (0.63; 0.88) 0.48 (0.39; 0.58) 
GSH 0.15 (0.08; 0.28) 1.72 (0.69; 4.31) 1.23 (0.43; 3.55) 1.08 (0.37; 3.13) * * 1.37 (0.97; 1.93) 0.75 (0.53; 1.08) 
Prior ANC testing: Tested 
≤22 weeks & 3rd trimester  
    
* * Ref Ref 
No prior ANC testing * * * * * * 0.37 (0.31; 0.43) 0.72 (0.55; 0.94) 
Tested ≤22 weeks only * * * * * * 0.77 (0.64; 0.92) 0.73 (0.61; 0.88) 
Tested 3rd trimester only * * * * * * 0.87 (0.74; 1.02) 0.84 (0.64; 1.10) 
*Not included in the model. 
†Only women that booked in the first window, weren’t diagnosed HIV-positive before delivery and delivered >5 days after the start of the third trimester were eligible for three tests. 
aOR: Adjusted odds ratio; CI: confidence interval; BBA: born before arrival; MPMOU: Mitchells Plain Midwife Obstetric Unit; MMH: Mowbray Maternity Hospital; MPDH: Mitchells Plain 
District Hospital; GSH: Groote Schuur Hospital; n: number of participants
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5. Discussion 
 
This is, to our knowledge, one of the first longitudinal studies of the implementation of 
maternal HIV testing guidelines in a routine setting in SA. The majority of women eligible for 
HIV testing tested at least once (91%). Although testing completion at “booking” was high 
(98%), women “booked” late with only 49% “booking” in the first recommended window. 
While HIV testing implementation improved over time, with fewer missed testing 
opportunities in the second year after guideline change, there were substantial missed 
testing opportunities with nearly a third of women not testing within 3 months of/at 
delivery and only 10% of eligible women being tested in all three recommended testing 
windows.  
The high initial HIV testing proportion in our study (91%) is encouraging however, with 9% of 
women never tested in pregnancy/delivery, it falls short of a) the global PMTCT target of 
having over 95% of pregnant women aware of their HIV status and b) the >95% “uptake of 
antenatal HIV testing” rate recorded for SA between 2010 – 2012 [15]. This observed 
difference may be due to our use of operational data from a single referral chain of health 
facilities in one area of Cape Town, including testing completeness in women presenting at 
delivery with no prior antenatal care, versus the use of nationwide aggregate antenatal 
survey data. This is underscored by the significant predictors of never HIV testing in 
pregnancy in our analysis: presenting for delivery “unbooked” vs. “booked” and older 
gestational age at “booking” (per additional week gestation), concurring with results from 
Zimbabwe [27]. These results suggest a need for additional interventions to improve the 
implementation of initial HIV testing among women who either “book” late in pregnancy or 
don’t “book”.  
In SA “booking” before 20 weeks gestational age, regardless of HIV status, is a PMTCT-
related indicator [15]. It is also recommended in national and WC guidelines that women are 
HIV tested at their first visit [8,10]. Reassuringly, the implementation of HIV testing at 
“booking” was excellent (98% coverage) but unfortunately many women “booked” late i.e. 
after 20 weeks gestation. Our analysis revealed that the median gestational age at 
“booking” for HIV-positive (at delivery) women was 24 weeks and the highest proportion 
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(1.6%) of HIV-positive diagnoses at enrolment was in the >22 - < 28 weeks gestation period. 
Further, a high proportion of women (15%) presented at delivery “unbooked” with HIV 
status unknown. Of the “unbooked” women who tested, 1.5% were HIV-positive which is 
possibly an underestimate as less than half of “unbooked” women received a HIV test. 
Untested women may have had a different HIV risk profile to tested women.  
Reassuringly, implementation of maternal HIV testing in our setting improved over time 
following the adoption of the updated retesting guidelines, similar to results from Kenya 
[23]. Women were less likely to miss testing opportunities if they enrolled in 2015/2016 as 
opposed to in 2014. Notwithstanding, we observed several missed repeat testing 
opportunities; a third of women had an unconfirmed HIV status after delivery as they had 
either never tested or last tested ≥3 months before delivery. This is however lower than that 
observed in Kenya [23]. Only a small proportion (10%) of eligible women received all three 
recommended HIV tests. Understandably, women who deliver prematurely are less likely to 
have all three tests however the data show that poor implementation of delivery testing 
was responsible for the bulk of missed opportunities. 
At delivery, women were more likely to HIV test at either of the two secondary level 
facilities (MPDH/MMH) versus MPMOU. At secondary facilities there were PMTCT nurses 
designated to do HIV testing. Women were often tested in the labour ward upon arrival, but 
otherwise had other opportunities to test in the post-natal ward if admitted after delivery. 
In primary care, women are often discharged within 6-8 hours of an uncomplicated birth. 
Nonetheless, women delivering at secondary facilities versus MPMOU were more likely to 
not test at all, possibly as “unbooked” (hence untested) women with high-risk 
pregnancies/deliveries are frequently transferred straight to secondary facilities for 
caesarean delivery, with no opportunity for testing in the labour ward. The transfer 
between facilities may also cause confusion regarding whether women were already tested.  
HIV prevalence among women with a known HIV status at delivery was 21%, similar to the 
19% reported for the WC [26]. Of the HIV-positive women the vast majority (95%) were 
known positive at enrolment indicating the maturity of the HIV programme with high overall 
testing coverage. It is also reassuring that the first of the 90-90-90 targets [15], that 90% of 
HIV-positive people know their status, has been met. It should however be noted that this 
proportion may be slightly overestimated due to missed positive diagnoses among women 
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that never tested. Furthermore, awareness of HIV status does not guarantee that women 
have initiated and adhered to ART. Future studies are required to assess viral load 
suppression among known positive women. The overall HIV incidence among women that 
initially tested HIV-negative was estimated to be 0.2% which is substantially lower than that 
previously reported in SA and SSA (3 – 4%), but similar to that of non-African countries 
(0.3%) [12,28]. While our study may substantially underestimate incidence due to the low 
completeness of repeat HIV testing, assessment of the most cost-effective number and 
timing of maternal HIV tests in different incidence settings, and feasibility of 
implementation, should be considered for future studies.  
Strengths and limitations:  
The use of individual-level longitudinal data allowed for a more accurate assessment of 
testing completion in recommended testing windows, based on each woman’s progress 
through the PMTCT continuum as opposed to using aggregate data. The use of longitudinal 
data also enabled the description of a) the timing of HIV-positive diagnoses and b) HIV 
incidence estimates. Point-of-care testing is not normally digitized so to our knowledge this 
is the only data of this kind available in SA. We had a large sample size which included 
antenatal and delivery HIV testing data from primary through tertiary care facilities.  
Positively, our study demonstrated the real-world implementation of PMTCT testing 
guidelines; however, we were dependent on the quality of operational data and couldn’t 
account for missing data. Furthermore, qualitative data were not routinely collected, and 
we could therefore not explore qualitative risk factors for missed testing opportunities. At 
visits other than “booking” and delivery, we did not have a record of visit data separate 
from testing data and therefore could not distinguish between visit coverage and re-testing 
coverage in the third trimester. Although we excluded women who attended any 
documented ANC visits at banc sites, we were unable to determine whether women had 
received point-of-care HIV testing at facilities not included in the study, or outside the WC 
province. The subset of women without recorded pregnancy outcomes may have had 
systematically different testing outcomes to those for whom outcomes were recorded and 
their exclusion from the dataset may therefore have introduced selection bias into the study 
results, thereby slightly overestimating testing completeness. Although the results of this 
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study may be externally valid to the WC, HIV testing is context-specific and results should be 
treated with caution when generalizing to other settings. 
 
6. Conclusion 
 
The results of this study illustrate that although there has been maturation of maternal HIV 
testing within the PMTCT programme over time, gaps remain in late pregnancy testing, 
particularly at delivery. Interventions are required at facility level to improve delivery HIV 
testing among women “booking” late/not “booking” and those that have high-risk 
pregnancies in order to limit the transition of undiagnosed HIV-positive women to the 
postnatal period without access to lifelong ART, feeding support and infant post-exposure 
prophylaxis. Additional research to assess a) the viral suppression among known HIV-
positive women and b) the cost-effectiveness of PMTCT testing guideline implementation is 
required. 
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PART D: APPENDICES 
Appendix 1: Supplementary methods 
 
 
Figure S1. Conceptual framework demonstrating the potential factors associated with HIV testing 
during PMTCT. Policy and individual level factors were investigated in this study. 
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Figure S2. Delivery HIV testing completion at respective delivery facilities. 
(n=6860). 
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MPMOU: Mitchells Plain Midwife Obstetric Unit; MPDH: Mitchells Plain District Hospital; MMH: Mowbray Maternity 
Hospital; GSH: Groote Schuur Hospital 
 
 
 
Table S1. Univariable and multivariable factors associated with failure to test at delivery among 
unbooked women (n=1016). 
 No delivery HIV testing  
Variable OR (95% CI) aOR (95% CI) 
Age at first visit (years) 0.95 (0.93; 0.97) 0.99 (0.96; 1.02) 
Gravidity: 1 Ref Ref 
2 0.73 (0.50; 1.07) 0.78 (0.51; 1.18) 
3 0.55 (0.37; 0.81) 0.66 (0.42; 1.05) 
≥4 0.37 (0.26; 0.52) 0.49 (0.30; 0.80) 
Premature delivery: Yes Ref Ref 
No 1.66 (1.08; 2.56) 1.68 (0.96; 2.97) 
Mode of delivery: Vaginal Ref Ref 
Assisted 0.52 (0.09; 3.12) 0.22 (0.03; 1.48) 
BBA 0.57 (0.38; 0.86) 0.78 (0.51; 1.21) 
Caesarean section 1.37 (0.89; 2.09) 0.83 (0.48; 1.42) 
Outcome: Alive Ref Ref 
Still Born 0.47 (0.23; 0.97) 0.72 (0.31; 1.63) 
Year of enrolment: 2014 Ref Ref 
2015/2016 0.35 (0.27; 0.47) 0.40 (0.30; 0.53) 
Delivery facility: MPMOU Ref Ref 
MPDH 1.96 (1.41; 2.73) 1.66 (1.09; 2.52) 
MMH 1.26 (0.78; 2.01) 1.62 (0.87; 3.00) 
GSH 0.66 (0.21; 2.09) 0.71 (0.20; 2.55) 
BBA: Born Before Arrival; MPMOU: Mitchells Plain Midwife Obstetric Unit; MPDH: Mitchells Plain District Hospital; 
MMH: Mowbray Maternity Hospital; GSH: Groote Schuur Hospital 
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Figure S3. Diagnoses among HIV-positive women (n=1345). 
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Appendix 3:  Closing the Gaps synopsis 
 
Towards pediatric HIV elimination: Closing the gaps in prevention of mother-to-child 
transmission (PMTCT) programme coverage, early infant diagnosis and treatment. (Short 
title: “Closing the Gaps”)  
 
1. Background and project outline  
Virtual elimination of vertical transmission of HIV is within reach in South Africa. Despite 
high antenatal HIV prevalence, implementation of currently available technology and 
guidelines in the South African Prevention of Mother-to-Child Transmission (PMTCT) 
programme has resulted in substantial reductions in vertically transmitted HIV to 3.5% 
across the country, and <2% in the Western Cape (WC). Yet, elimination remains elusive due 
to persistent coverage gaps and “drop-offs” at each of the steps required in completion of 
the PMTCT and infant care continuum, with upwards of 1000 vertically infected infants born 
in the Western Cape each year. We hypothesize that these persistent coverage gaps are the 
most important remaining barrier to near-elimination of pediatric HIV morbidity and 
mortality, irrespective of intensification of PMTCT regimens.  
There is thus a need for research to identify strategies that provide an early warning system 
of coverage gaps both at the level of the health system and the individual, and link to care 
pregnant women and HIV-exposed/infected infants with such gaps who critically need 
antiretroviral therapy (ART) or interventions to prevent transmission.  
2. Purpose and objectives:  
The purpose of this study is to implement and evaluate three linked active surveillance 
activities integrated with the existing service platform that aim to iteratively identify and 
close PMTCT, early infant diagnosis and ART coverage gaps. The study will be carried out by 
the Centre for Infectious Disease Epidemiology and Research (CIDER) from the UCT School 
of Public Health and Family Medicine in partnership with the WC Department of Health 
(DoH). The study will be conducted at the Gugulethu Midwife Obstetric Unit (GMOU) in the 
78 
 
Klipfontein sub-district, and its referral facilities, Mowbray Maternity Hospital (MMH) and 
Groote Schuur Hospital (GSH). The three activities are as follows:  
1. Routine cord blood surveillance (CBS) for HIV exposure and, if positive, the presence of 
antiretroviral drugs (ARVs): This will be linked to the existing programme of screening for 
congenital hypothyroidism. CBS will enable identification and urgent linking to care of HIV-
exposed infants with no/suboptimal peripartum ARVs to ensure interventions to prevent 
postnatal transmission, prompt infant diagnosis and infant ART if infected.  
2. A single integrated electronic PMTCT register (e-register) linking existing separate paper-
based registers held at antenatal, obstetric and infant clinics in the Klipfontein subsdistrict, 
as well as NHLS laboratory data (maternal CD4, infant PCR). Unlike existing registers that 
report on aggregate coverage of individual steps in the PMTCT pathway, the combined e-
register will track an individual pregnant woman’s trajectory through PMTCT and identify 
where drop-offs and missed opportunities occur. The e-register will therefore support 
systems of urgent reporting of laboratory results of low CD4 counts in pregnant women and 
positive infant HIV-PCR test results to clinics, with tracing to ensure prompt ART initiation.  
3. Clinical quality assurance and improvement using CBS and PMTCT e-register data. This 
will be developed in partnership with DoH service managers and integrated with existing 
subdistrict programme review processes.  
These activities thus aim to close coverage gaps at 2 levels:  
At an individual level: For individual mothers and infants interventions are designed to 
ensure appropriate linkages to care will be triggered at key points in the PMTCT cascade.  
At a health system level: An auditable early warning system of coverage gaps across the 
entire program, and interrogation of the reasons for ongoing vertical transmission, will 
inform and be integrated into clinical quality assurance systems.  
Objectives of the study are therefore as follows:  
1. To compare PMTCT programme outcomes and effectiveness before and after 
implementation of these surveillance activities. Measures of programme outcomes and 
effectiveness to be compared will include:  
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• Vertical transmission proportion  
• Proportion of women presenting at delivery without a previous HIV test  
• Proportion of women with incident HIV infection during pregnancy  
• Proportion of mother-infant pairs “dropping off” at each step of the cascade (e-register 
and CBS).  
2. To assess the feasibility and success of implementation of the project by measuring, for 
example, CBS coverage, completeness and quality of PMTCT e-register data entry and 
linkage, proportion of those identified by the e-register and/or CBS as needing additional 
intervention who are successfully traced and linked to appropriate care, compliance with 
clinical quality assurance review meetings.  
All data needed for the above objectives will be collected through implementation of CBS 
and the e-register.  
3. Implementation and recruitment  
Briefly we aim to implement the 3 activities as follows:  
3.1. Cord blood surveillance  
The project will build on the existing system of congenital hypothyroidism screening, using 
routine systems for collection of a specimen of cord blood, specimen transport, registration 
and testing. A research assistant will visit GMOU, MMH and GSH twice a week to support 
and monitor the collection of cord-blood specimens. Recruitment of pregnant women ≥18 
years of age will take place at the antenatal booking visit at GMOU. As part of counselling 
and testing for routine opt-out antenatal HIV testing that is standard of care, a study 
counsellor will work with existing counselling staff to obtain informed consent (IC) to 
participate in the study. This will include consent for a rapid HIV test to be performed on a 
cord blood specimen taken at delivery and, if HIV positive, 2 dried blood spot specimens to 
be tested for the presence of ARVs. HIV tests will be performed at the NHLS laboratory at 
Red Cross Children’s Hopsital and tests for ARVs at the UCT Department of Pharmacology. 
The process of obtaining IC will include explaining the risks and benefits of participation 
(including that testing may lead to more active tracing and follow-up of the patient if results 
indicate that there is a high risk of transmission), the alternatives to participation, and that 
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the decision to participate will in no way affect the medical care provided. Patients 
consenting to participate in the study will be provided with an information sheet and 
informed that they may withdraw from the study at any time. In particular, at delivery, 
women will be reminded that they have given consent for cord blood testing, and given the 
opportunity to withdraw from the study. For women who arrive at GMOU in labour without 
a previous antenatal booking, we will attempt to obtain consent during labour to participate 
in the study. This will be done to ensure that coverage of CBS is as complete as possible, and 
that “unbooked” women are also able to access the benefits of study participation. All 
consent procedures, information sheets and reminders of study involvement will be 
performed/translated into all local languages.  
Infants at high risk of HIV infection (cord blood HIV positive, no/sub-optimal ARVs) will be 
traced and linked to care by a study community outreach worker working with existing 
health service PMTCT support staff. This will include counseling regarding the HIV diagnosis 
to the mother if this was previously unknown. Mother-infant pairs will be linked to routine 
PMTCT/MCH services so that interventions to reduce the risk of postnatal transmission as 
well as early infant PCR testing (with early ART if positive) can be provided. Data from HIV-
exposed infants with ARVs present in cord blood will be linked to laboratory data to 
determine whether PCR testing occurs timeously. The same tracing staff will seek infants 
not tested by 8 weeks of age and link them to care.  
2. Electronic PMTCT Register  
PMTCT data from women delivering at GMOU as well as women referred from GMOU to 
MMH and GSH, will be linked with data from the antenatal and infant follow-up clinics 
associated with GMOU, as well as with laboratory data to establish a single PMTCT e-
register. Linkage fields will include the WC unique patient health numbers, maternal and 
infant names, birth dates, delivery dates and infant birth dates. A very high proportion of 
true matches are readily linkable when the linkage sets are restricted by location (facility) or 
date (e.g. birth date of infant and delivery date of mother). The proportion of records that 
cannot be linked will indicate the disjunction in each step in the PMTCT continuum, 
providing early warning of coverage gaps.  
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The e-register will support urgent notification of clinics of laboratory results of maternal CD4 
<350 cells/μl and positive infant PCR tests. These will be identified through daily updates of 
laboratory results from the NHLS to the research officer at CIDER for incorporation into the 
e-register. The research officer will work with existing reporting systems to inform the 
relevant clinic/health service staff of any positive test results. We will work with existing WC 
and City of Cape Town HIV/AIDS and PMTCT to ensure tracing and treatment initiation for 
these HIV-infected women and infants needing ART.  
There will be no recruitment and we are requesting a waiver of informed consent for this 
part of the project. We will only be incorporating data already collected as part of routine 
care by the health services and for which informed consent was given when women 
consented to standard of care routine antenatal opt-out HIV testing.  
3. Clinical quality assurance and improvement  
Monthly program reviews will be implemented in partnership with Department of Health 
service managers and be informed by data arising from the PMTCT e-register and CBS. For 
example:  
• Sentinel events of new cases of infant HIV identified through the e-register will be 
reviewed to identify reasons for transmission.  
• Coverage gaps at each step of the PMTCT cascade in women on the PMTCT program as 
identified through the e-register will be reviewed.  
• Coverage gaps in all steps of the cascade up to and including delivery as measured by CBS 
data will be reviewed.  
No maternal or infant identifiers will be used or mentioned at all in these reviews.  
4. Description of risks and benefits:  
4.1. Potential risks to subjects and their likelihood and seriousness  
The major risk for all 3 components will be breach of confidentiality - project staff will have 
access to individually identifiable maternal and infant HIV and ARV cord blood results, and 
trace high risk transmission mother-infant pairs. A small number of women will be recruited 
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for CBS in labour and this may pose a psychological risk. Patient autonomy may also be 
compromised and privacy breached, as the circumstances in labour may not provide 
adequate opportunity for counseling and informed consent according to service protocol. 
This could be considered morally controversial. However, it is argued that withholding the 
right to consent to HIV testing and treatment to a woman of unknown serostatus 
compromises her autonomy to have the choice of her infant receiving interventions to 
prevent vertical transmission if she is HIV infected, even if consent needs to be sought 
during labour. The study offers clear benefits to mother-infant pairs identified as HIV 
infected for the first-time at delivery (opportunity to receive proven effective interventions 
to prevent post-natal transmission, active follow-up and linkage to HIV/ART care) so it 
would be unethical to exclude women presenting for the first time when already in labour. 
This is the group for whom the benefits of participation may be the greatest. Rapid HIV 
testing in labour is recommended in other service settings e.g. “opt out” testing in labour for 
a woman of unknown serostatus is standard of care in the United States.  
4.2. Adequacy of Protection Against Risks  
The process of obtaining informed consent for CBS in such a way as to minimize risks, 
ensure that women fully understand the risks of participation and have autonomy to refuse 
participation or withdraw from the study have been described above. In particular, we will 
only use qualified HIV Counseling and Testing (HCT) counselors and will employ additional 
counselors to support DoH counselors to ensure adequate quality of the informed consent 
process. For women recruited during labour we will ensure that counseling is conducted in 
privacy and that the benefits and risks of cord blood HIV testing are fully explained. Since a 
pregnant woman in labour is particularly vulnerable, we will be sure that women clearly 
understand that the quality of health care they receive will not be compromised should they 
elect not to participate. Should a woman with no prior antenatal care present too late in 
labour for there to be time for her to be invited to participate in the study, the midwife will 
collect the additional cord blood specimen, and after delivery is complete, the woman will 
be invited to participate in the study and have the specimen tested for HIV/ARVs. Specimens 
from women who decline to participate post-delivery will be discarded.  
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Tracing and linkage to care of pregnant women eligible for ART and infants identified as HIV-
infected or at high risk of vertical transmission will be done carefully and sensitively. 
Pregnant women/mothers of infants will be telephoned and asked to attend the clinic 
urgently for a health care appointment. Where telephonic tracing is unsuccessful, a home 
visit will be done and the patient asked to attend the clinic for a health care appointment. 
No laboratory results will be given to the mother telephonically or at the home visit. Results 
will only be given to the mother at the clinic appointment in a private room by qualified 
health service providers as per South African PMTCT and HCT guidelines ensuring patient 
confidentiality. Full post-test counselling will be given to the mother according to HCT 
guidelines.  
All HIV counselling and testing (antenatally and during labour or post-delivery) will be 
offered by qualified health service providers as per HCT and PMTCT guidelines ensuring 
patient confidentiality and autonomy.  
To minimize risks of breaching confidentiality, all electronic project data will be stored in a 
password-protected database on a secure server housed in the CIDER offices at the UCT 
Faculty of Health Sciences, with user level access control implemented. Any paper-based 
patient records will be stored in locked filing cabinets in locked room with access only to 
those directly involved in the study. Inclusion of identifiers in the databases is needed 
initially so that they can be linked and for tracing of mothers/infants. Identifiers will be 
removed from all databases (PMTCT e-register and CBS HIV and ARV results) as soon as 
possible once linkage and tracing are complete. Only staff directly involved in the project 
will have access to the data and will undergo Human Subjects Protection training prior to 
having access to any individually identifiable data. We will use the same measures to protect 
against breach of confidentiality as are currently in place in all CIDER projects. Thus far, no 
breach of confidentiality has occurred in any of these projects. Should a breach of 
confidentiality occur in this project, it will be noted and investigated.  
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4.3 Potential benefits  
Historically, antenatal sentinel surveillance and monitoring of PMTCT programmes has been 
based on anonymous specimens and aggregate data. While these provide surveillance for 
the programme as a whole, they provide no opportunity to act on clinically important 
results, and thus fail to benefit the individual patient on whom testing has been performed.  
This study thus has the following benefits:  
• It will generate surveillance data and early warning systems that will trigger and inform 
PMTCT programme improvement, thus benefiting all HIV-infected mother-infants pairs in 
the area where the study takes place.  
• It provides individual benefit to mothers and infants participating in the study by 
identifying pregnant women eligible for ART, HIV-infected infants and those at high risk of 
transmission and prioritizing provision of immediate PMTCT and maternal and infant HIV 
care interventions that are known to be effective and safe. All pregnant women ≥18 years of 
age will be invited to join the study and have access to these benefits.  
• The surveillance systems will be developed in partnership with health services with a long 
term view to more widespread routine adoption, so that HIV-infected women and exposed 
infants from other areas will also benefit if the project is successfully expanded to other 
areas and integrated into routine surveillance.  
• The findings of the study will inform PMTCT programmes broadly in terms of improving 
coverage and maximizing the benefits of ART for maternal and child health.  
4.4. Balancing the major risks to subjects with the potential benefits of the project  
Breach of confidentiality: As every effort will be taken to ensure confidentiality, the small 
risk of it being breached can be considered to be acceptable given the potential not only to 
achieve PMTCT programmatic improvements, but also to provide individual benefit to study 
participants through tracing and linkage to care. Of note, the individual benefits could not 
be provided without the holding of identified laboratory test results, so this is an 
unavoidable risk.  
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Compromise of patient autonomy and psychological distress for women recruited during 
labour:  
While optimal strategies for PMTCT comprise early antenatal diagnosis and treatment, 
testing pregnant women of either unknown serostatus or with acute infection at the time of 
delivery provides an additional opportunity for PMTCT. Given the availability of effective 
maternal and infant ART the potential immediate benefit to mother and child of a pregnant 
woman learning her serostatus peripartum has increased relative to the potential risks of 
offering HIV testing in this setting. 
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Appendix 4: UCT Human Research Ethics Committee approval (145/2013); 
PGWC Health Research approval (RP063/2013) (CTG) 
 
  
87 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
Appendix 5: UCT Human Research Ethics Committee approval (779/2018) 
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Title page  
The title should not contain abbreviations, except commonly used abbreviations such as HIV 
or AIDS (see Wiley's best practice SEO tips). 
On the title page, you should mention the title of the manuscript, list all authors' names in 
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headings of the selected article category (see above), excluding the heading “Discussion” for 
Research articles. Avoid using abbreviations and do not cite references in the Abstract. If 
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Article sections  
Introduction 
The Introduction section should introduce the topic to readers without specialist knowledge 
in that area and must clearly outline the current state of knowledge in this field, the 
motivation and the aim of the study or the article.  
 
Methods 
The Methods section should include all information necessary to repeat the study, in 
particular, the study design, how data was collected and analyzed, clarifying the choice of 
methods that were made. If applicable, you should describe the setting of the study, the 
dates the study were conducted, and the sample or participants, as well as necessary power 
calculations and materials, including statistical packages, used. Interventions and 
programmes should be described in detail. Generic names for drugs or any molecules should 
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All studies involving humans or animals require a statement on ethical approval, and for the 
former, the consent procedure that was followed. Please include the names of the ethics 
review board(s) that approved the study. If the research study was specific to one 
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Results 
This section should include only data and findings from the authors' study. Presentation of 
statistical results should mention confidence intervals and levels of significance where 
appropriate. Quotes from qualitative study participants of less than three lines should be 
quoted in the text using quotation marks. For quotes longer than three lines, place the 
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are needed in this case. Details of the participant can be added in round brackets following 
the quote, but should not contain identifiable information to ensure confidentiality. 
Clarifications within the quotation should be placed in square brackets. 
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physiological differences between men and women (height, weight, body fat-to-muscle 
ratios, cell counts, hormonal cycles, etc.), as well as social and cultural variables (socio-
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Discussion 
In the Discussion section, you should discuss your main findings and place these within the 
context of the current body of knowledge in the field. Limitations of the study, for example, 
selection bias, can also be discussed, and should address how these influence the results 
and conclusions. If statistically significant differences were found between men and women 
or between different racial or cultural groups in the effects of the studied intervention, the 
implications, if any, for clinical and/or public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their 
importance and relevance, as well as implications. Future studies and recommendations can 
be included in this section. The conclusions drawn must be strictly based on the data 
provided. 
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